{"DataElement":{"publicId":"2757914","version":"1","preferredName":"Agent Administered Name","preferredDefinition":"the name of the agent administered.","longName":"AGT_ADM_NM","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2013308","version":"3","preferredName":"Agent Administered","preferredDefinition":"the administration of an agent or drug to a patient.","longName":"AGT_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2223333","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F62B10F2-76A7-2830-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-02","endDate":null,"createdBy":"UMLLOADER","dateCreated":"2005-05-02","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABF4E934-6983-6484-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-02-06","endDate":null,"createdBy":"PWEST","dateCreated":"2002-10-01","modifiedBy":"REEVESD","dateModified":"2016-06-29","changeDescription":"Use caBIG NCIt based OC instead. - dw","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2757908","version":"1","preferredName":"Agent Administered Name","preferredDefinition":"the name of the agent administered.","longName":"AGT_ADM_NM","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Paclitaxel","valueDescription":"Paclitaxel","ValueMeaning":{"publicId":"2739551","version":"1","preferredName":"Paclitaxel","longName":"2739551","preferredDefinition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-0248-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F5148FD-83C3-3F65-E044-0003BA3F9857","beginDate":"2008-06-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"CAMPBELB","dateModified":"2008-06-10","deletedIndicator":"No"},{"value":"FEC","valueDescription":"Cyclophosphamide/Epirubicin/Fluorouracil","ValueMeaning":{"publicId":"2757910","version":"1","preferredName":"Cyclophosphamide/Epirubicin/Fluorouracil","longName":"2757910v1.00","preferredDefinition":"A chemotherapy regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide, used as a treatment for recurrent and metastatic breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FEC Regimen","conceptCode":"C9595","definition":"A chemotherapy regimen consisting of fluorouracil, epirubicin and intravenous cyclophosphamide, used as a treatment for recurrent and metastatic breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-83D2-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"KUMMEROA","dateModified":"2023-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F5148FD-83EB-3F65-E044-0003BA3F9857","beginDate":"2008-06-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"CAMPBELB","dateModified":"2008-06-10","deletedIndicator":"No"},{"value":"Cyclophosphamide","valueDescription":"Cyclophosphamide","ValueMeaning":{"publicId":"2757911","version":"1","preferredName":"Cyclophosphamide","longName":"2757911","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-83F7-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"KUMMEROA","dateModified":"2022-09-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F5148FD-8410-3F65-E044-0003BA3F9857","beginDate":"2008-06-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"CAMPBELB","dateModified":"2008-06-10","deletedIndicator":"No"},{"value":"Epirubicin","valueDescription":"Epirubicin","ValueMeaning":{"publicId":"2757913","version":"1","preferredName":"Epirubicin","longName":"2757913","preferredDefinition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Epirubicin","conceptCode":"C62028","definition":"A 4'-epi-isomer of the anthracycline antineoplastic antibiotic doxorubicin.  Epirubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis.  This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-841F-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F5148FD-8438-3F65-E044-0003BA3F9857","beginDate":"2008-06-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"CAMPBELB","dateModified":"2008-06-10","deletedIndicator":"No"},{"value":"Fluorouracil","valueDescription":"Fluorouracil","ValueMeaning":{"publicId":"2717921","version":"1","preferredName":"Fluorouracil","longName":"2717921","preferredDefinition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity.  Fluorouracil and its metabolites possess a number of different mechanisms of action.  In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.  Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), a necessary constituent of DNA.  Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both the processing and functions of RNA. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fluorouracil","conceptCode":"C505","definition":"An antimetabolite fluoropyrimidine analog of the nucleoside pyrimidine with antineoplastic activity. Fluorouracil and its metabolites possess a number of different mechanisms of action. In vivo, fluoruracil is converted to the active metabolite 5-fluoroxyuridine monophosphate (F-UMP); replacing uracil, F-UMP incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth. Another active metabolite, 5-5-fluoro-2'-deoxyuridine-5'-O-monophosphate (F-dUMP), inhibits thymidylate synthase, resulting in the depletion of thymidine triphosphate (TTP), one of the four nucleotide triphosphates used in the in vivo synthesis of DNA. Other fluorouracil metabolites incorporate into both RNA and DNA; incorporation into RNA results in major effects on both RNA processing and functions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42BFA254-C2F6-032A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-01-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"4F5148FD-8444-3F65-E044-0003BA3F9857","beginDate":"2008-06-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"CAMPBELB","dateModified":"2008-06-10","deletedIndicator":"No"},{"value":"Tamoxifen","valueDescription":"Tamoxifen","ValueMeaning":{"publicId":"2897675","version":"1","preferredName":"Tamoxifen","longName":"2897675","preferredDefinition":"An antineoplastic nonsteroidal selective estrogen receptor modulator (SERM).  Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA.  The result is a reduction in DNA synthesis and cellular response to estrogen.  In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tamoxifen Citrate","conceptCode":"C855","definition":"The citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B75B6A8-FB2B-BC7B-E040-BB89AD4323EC","latestVersionIndicator":"Yes","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"FINCHAMB","dateModified":"2022-11-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B75B6A8-FB44-BC7B-E040-BB89AD4323EC","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"ONEDATA","dateModified":"2009-06-03","deletedIndicator":"No"},{"value":"Aromatase Inhibitor","valueDescription":"Aromatase Inhibitor","ValueMeaning":{"publicId":"2897676","version":"1","preferredName":"Aromatase Inhibitor","longName":"2897676","preferredDefinition":"An agent that blocks the function of the enzyme aromatase with antineoplastic activity.  Aromatase inhibitors belong to two classes: Type I steroidal drugs are androgen substrate analogues that bind competitively but irreversibly to the enzyme.  Type II nonsteroidal inhibitors fit into the substrate binding site and bind reversibly to the enzyme.  Present in many tissues, aromatases are heme-containing enzymes that catalyze the adrenal conversion of cholesterol to pregnenolone and the peripheral conversion (aromatization) of androgenic precursors to estrogens. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aromatase Inhibitor","conceptCode":"C1740","definition":"Any substance that inhibits aromatase, an enzyme responsible for the conversion of cholesterol to pregnenolone and the peripheral aromatization of androgenic precursors into estrogens. Inhibition of aromatase results in the suppression of estrogen-regulated processes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B75B6A8-FB4E-BC7B-E040-BB89AD4323EC","latestVersionIndicator":"Yes","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"FINCHAMB","dateModified":"2022-11-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B75B6A8-FB67-BC7B-E040-BB89AD4323EC","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"ONEDATA","dateModified":"2009-06-03","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B75B6A8-FB71-BC7B-E040-BB89AD4323EC","beginDate":"2009-06-03","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2009-06-03","modifiedBy":"ONEDATA","dateModified":"2009-06-03","deletedIndicator":"No"},{"value":"Docetaxel","valueDescription":"Docetaxel","ValueMeaning":{"publicId":"2576637","version":"1","preferredName":"Docetaxel","longName":"2576637","preferredDefinition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Docetaxel","conceptCode":"C1526","definition":"A semi-synthetic, second-generation taxane derived from a compound found in the European yew tree, Taxus baccata.  Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death.  This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response.  Docetaxel has been studied for use as a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87E7A12-E280-7444-E040-BB89AD4326B2","beginDate":"2012-08-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"Doxorubicin","valueDescription":"Doxorubicin","ValueMeaning":{"publicId":"2561008","version":"1","preferredName":"Doxorubicin","longName":"2561008","preferredDefinition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Doxorubicin","conceptCode":"C456","definition":"An anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BB5D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-04-11","endDate":null,"createdBy":"JASUR","dateCreated":"2002-04-11","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C87E7A12-E28A-7444-E040-BB89AD4326B2","beginDate":"2012-08-30","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-08-30","modifiedBy":"ONEDATA","dateModified":"2012-08-30","deletedIndicator":"No"},{"value":"LHRH Agonist","valueDescription":"LHRH agonist","ValueMeaning":{"publicId":"2573099","version":"1","preferredName":"LHRH agonist","longName":"2573099","preferredDefinition":"A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gonadotropin-releasing Hormone Analog","conceptCode":"C1910","definition":"A synthetic analogue of the endogenous hormone gonadotropin-releasing hormone (GnRH), with potential antineoplastic activity. Upon administration, GnRH analogue mimics endogenous GnRH and strongly binds to and activates pituitary GnRH receptors, which stimulates the synthesis and secretion of the gonadotropic hormones, follicle stimulating hormone (FSH) and luteinizing hormone (LH). Continuous, prolonged activation by the GnRH analogue results in pituitary GnRH receptor desensitization and receptor downregulation. This causes inhibition of pituitary gonadotropin secretion of LH and FSH. In males, the inhibition of LH secretion prevents the production and release of testosterone from Leydig cells in the testes and causes a significant decline in testosterone production that is near the levels seen after castration. This may inhibit androgen receptor-positive tumor progression. In females, this results in a decrease in estradiol production. GnRH, also called luteinizing hormone-releasing hormone (LH-RH), is normally synthesized in and secreted by the hypothalamus. Synthetic analogues of GnRH have a stronger receptor binding affinity than the endogenous form.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EA98-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-08","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-08","modifiedBy":"COOPERM","dateModified":"2016-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BB4E5216-86AA-0285-E040-BB89AD433E1C","beginDate":"2012-03-15","endDate":null,"createdBy":"BRETTS","dateCreated":"2012-03-15","modifiedBy":"ONEDATA","dateModified":"2012-03-15","deletedIndicator":"No"},{"value":"GM-CSF","valueDescription":"GM-CSF","ValueMeaning":{"publicId":"2576458","version":"1","preferredName":"GM-CSF","longName":"2576458","preferredDefinition":"Granulocyte-macrophage colony-stimulating factor. A colony-stimulating factor that stimulates the production of white blood cells, especially granulocytes and macrophages, and cells (in the bone marrow) that are precursors of platelets. It is a cytokine that belongs to the family of drugs called hematopoietic (blood-forming) agents. Also called sargramostim.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Granulocyte-Macrophage Colony-Stimulating Factor","conceptCode":"C1288","definition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous glycoprotein cytokine growth factor granulocyte-macrophage colony stimulating factor (GM-CSF). Therapeutic GM-CSF induces the clonal expansion and differentiation of progenitor blood cells and stimulates the cytotoxicity of monocytes and neutrophils, thereby restoring immune function and host antitumor immune responses and stimulating engraftment of transplanted bone marrow tissue. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F7B7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-07","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-07","modifiedBy":"SHIDED","dateModified":"2013-05-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CAB1DA52-E759-FF72-E040-BB89AD436B31","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"ONEDATA","dateModified":"2012-09-27","deletedIndicator":"No"},{"value":"ch14.18","valueDescription":"Monoclonal Antibody Ch14.18","ValueMeaning":{"publicId":"3597790","version":"1","preferredName":"Monoclonal Antibody Ch14.18","longName":"3597790","preferredDefinition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Monoclonal antibody Ch14.18 binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dinutuximab","conceptCode":"C1570","definition":"A chimeric mouse/human monoclonal antibody with potential antineoplastic activity. Dinutuximab binds to the ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells.  GD2 is overexpressed in malignant melanoma, neuroblastoma, osteosarcoma, and small cell carcinoma of the lung.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CAB1DA52-E763-FF72-E040-BB89AD436B31","latestVersionIndicator":"Yes","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CAB1DA52-E77C-FF72-E040-BB89AD436B31","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"ONEDATA","dateModified":"2012-09-27","deletedIndicator":"No"},{"value":"Temsirolimus","valueDescription":"Temsirolimus","ValueMeaning":{"publicId":"3380203","version":"1","preferredName":"Temsirolimus","longName":"3380203","preferredDefinition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temsirolimus","conceptCode":"C1844","definition":"An ester analog of rapamycin. Temsirolimus binds to and inhibits the mammalian target of rapamycin (mTOR), resulting in decreased expression of mRNAs necessary for cell cycle progression and arresting cells in the G1 phase of the cell cycle. mTOR is a serine/threonine kinase which plays a role in the PI3K/AKT pathway that is upregulated in some tumors.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D73C-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CAB1DA52-E786-FF72-E040-BB89AD436B31","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"ONEDATA","dateModified":"2012-09-27","deletedIndicator":"No"},{"value":"Temozolomide","valueDescription":"Temozolomide","ValueMeaning":{"publicId":"3380202","version":"1","preferredName":"Temozolomide","longName":"3380202","preferredDefinition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of  DNA replication.  Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Temozolomide","conceptCode":"C1244","definition":"A triazene analog of dacarbazine with antineoplastic activity.  As a cytotoxic alkylating agent, temozolomide is converted at physiologic pH to the short-lived active compound, monomethyl triazeno imidazole carboxamide (MTIC). The cytotoxicity of MTIC is due primarily to methylation of DNA at the O6 and N7 positions of guanine, resulting in inhibition of DNA replication. Unlike dacarbazine, which is metabolized to MITC only in the liver, temozolomide is metabolized to MITC at all sites. Temozolomide is administered orally and penetrates well into the central nervous system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A755C-D717-40C9-E040-BB89AD4320DE","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"COLBERTM","dateModified":"2024-01-02","changeDescription":null,"administrativeNotes":"1/2/24 Added Temodar as alt name for PCDC. mr","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CAB1DA52-E790-FF72-E040-BB89AD436B31","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"ONEDATA","dateModified":"2012-09-27","deletedIndicator":"No"},{"value":"Irinotecan","valueDescription":"Irinotecan","ValueMeaning":{"publicId":"3597791","version":"1","preferredName":"Irinotecan","longName":"3597791","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Irinotecan","conceptCode":"C62040","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.  Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme.  One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death.  Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CAB1DA52-E79C-FF72-E040-BB89AD436B31","latestVersionIndicator":"Yes","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"CAB1DA52-E7B4-FF72-E040-BB89AD436B31","beginDate":"2012-09-27","endDate":null,"createdBy":"WONGW","dateCreated":"2012-09-27","modifiedBy":"ONEDATA","dateModified":"2012-09-27","deletedIndicator":"No"},{"value":"Melphalan","valueDescription":"Melphalan","ValueMeaning":{"publicId":"2654276","version":"1","preferredName":"Melphalan","longName":"2654276","preferredDefinition":"An orally available phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32CD72AB-9FA5-289C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-13","endDate":null,"createdBy":"ALAIS","dateCreated":"2007-06-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D36B1B10-B12E-45C4-E040-BB89AD4326AB","beginDate":"2013-01-16","endDate":null,"createdBy":"WONGW","dateCreated":"2013-01-16","modifiedBy":"ONEDATA","dateModified":"2013-01-16","deletedIndicator":"No"},{"value":"Busulfan","valueDescription":"Busulfan","ValueMeaning":{"publicId":"2739539","version":"1","preferredName":"Busulfan","longName":"2739539","preferredDefinition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Busulfan","conceptCode":"C321","definition":"A synthetic derivative of dimethane-sulfonate with antineoplastic and cytotoxic properties.  Although its mechanism of action is not fully understood, busulfan appears to act through the alkylation of DNA.  Following systemic absorption of busulfan, carbonium ions are formed, resulting in DNA alkylation and DNA breaks and inhibition of DNA replication and RNA transcription. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBD0-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D36B1B10-B138-45C4-E040-BB89AD4326AB","beginDate":"2013-01-16","endDate":null,"createdBy":"WONGW","dateCreated":"2013-01-16","modifiedBy":"ONEDATA","dateModified":"2013-01-16","deletedIndicator":"No"},{"value":"Crizotinib","valueDescription":"Crizotinib","ValueMeaning":{"publicId":"3377031","version":"1","preferredName":"Crizotinib","longName":"3377031","preferredDefinition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Crizotinib","conceptCode":"C74061","definition":"An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B89EC9E2-49F5-54C4-E040-BB89AD432648","latestVersionIndicator":"Yes","beginDate":"2012-02-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6D48009-2629-7E54-E040-BB89AD43171F","beginDate":"2013-09-20","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-20","modifiedBy":"ONEDATA","dateModified":"2013-09-20","deletedIndicator":"No"},{"value":"Brentuximab Vedotin","valueDescription":"Brentuximab Vedotin","ValueMeaning":{"publicId":"3228385","version":"1","preferredName":"Brentuximab Vedotin","longName":"3228385","preferredDefinition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Brentuximab Vedotin","conceptCode":"C66944","definition":"An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A16046E6-D6A0-1B8D-E040-BB89AD434ADA","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-20","modifiedBy":"KUMMEROA","dateModified":"2023-03-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E6D48009-265E-7E54-E040-BB89AD43171F","beginDate":"2013-09-20","endDate":null,"createdBy":"WONGW","dateCreated":"2013-09-20","modifiedBy":"ONEDATA","dateModified":"2013-09-20","deletedIndicator":"No"},{"value":"Imetelstat","valueDescription":"Imetelstat","ValueMeaning":{"publicId":"3379084","version":"1","preferredName":"Imetelstat","longName":"3379084","preferredDefinition":"A synthetic lipid-conjugated, 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase (hTR) RNA, imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a telomerase template antagonist), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imetelstat","conceptCode":"C49084","definition":"A synthetic lipid-conjugated, 13-mer oligonucleotide N3'-P5'-thio-phosphoramidate with potential antineoplastic activity. Complementary to the template region of telomerase (hTR) RNA, imetelstat acts as a competitive enzyme inhibitor that binds and blocks the active site of the enzyme (a telomerase template antagonist), a mechanism of action which differs from that for the antisense oligonucleotide-mediated inhibition of telomerase activity through telomerase mRNA binding. Inhibition of telomerase activity in tumor cells by imetelstat results in telomere shortening, which leads to cell cycle arrest or apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-55D1-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EDA9322A-9E44-B123-E040-BB89AD4315AD","beginDate":"2013-12-16","endDate":null,"createdBy":"WONGW","dateCreated":"2013-12-16","modifiedBy":"ONEDATA","dateModified":"2013-12-16","deletedIndicator":"No"},{"value":"Ganitumab","valueDescription":"Ganitumab","ValueMeaning":{"publicId":"3232380","version":"1","preferredName":"Ganitumab","longName":"3232380","preferredDefinition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Ganitumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a tyrosine kinase and a member of the insulin receptor family. IGF-1R activation stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ganitumab","conceptCode":"C71531","definition":"A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Ganitumab binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. IGF-1R is a tyrosine kinase and a member of the insulin receptor family. IGF-1R activation stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A1FA4B23-07F8-5DC7-E040-BB89AD4327C7","latestVersionIndicator":"Yes","beginDate":"2011-04-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-04-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F55E031E-298E-9080-E040-BB89AD4341A2","beginDate":"2014-03-24","endDate":null,"createdBy":"WONGW","dateCreated":"2014-03-24","modifiedBy":"ONEDATA","dateModified":"2014-03-24","deletedIndicator":"No"},{"value":"Eribulin","valueDescription":"Eribulin","ValueMeaning":{"publicId":"4311896","version":"1","preferredName":"Eribulin","longName":"4311896","preferredDefinition":"An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Eribulin","conceptCode":"C96748","definition":"An analogue of halichondrin B, a substance derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F96171AF-8CBE-CD50-E040-BB89AD436A46","latestVersionIndicator":"Yes","beginDate":"2014-05-14","endDate":null,"createdBy":"WANGC","dateCreated":"2014-05-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F96171AF-8CD7-CD50-E040-BB89AD436A46","beginDate":"2014-05-14","endDate":null,"createdBy":"WANGC","dateCreated":"2014-05-14","modifiedBy":"ONEDATA","dateModified":"2014-05-14","deletedIndicator":"No"},{"value":"Other, specify","valueDescription":"Other, specify","ValueMeaning":{"publicId":"2570886","version":"1","preferredName":"Other, specify","longName":"2570886","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E1F3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-06-21","endDate":null,"createdBy":"SBR","dateCreated":"2004-06-21","modifiedBy":"CAMPBELB","dateModified":"2013-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D551-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Zoledronic Acid","valueDescription":"Zoledronic Acid","ValueMeaning":{"publicId":"4147712","version":"1","preferredName":"Zoledronic Acid","longName":"4147712v1.00","preferredDefinition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Zoledronic Acid","conceptCode":"C1699","definition":"A synthetic imidazole bisphosphonate analog of pyrophosphate with anti-bone-resorption activity. A third-generation bisphosphonate, zoledronic acid binds to hydroxyapatite crystals in the bone matrix, slowing their dissolution and inhibiting the formation and aggregation of these crystals. This agent also inhibits farnesyl pyrophosphate synthase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. Decreased bone turnover and stabilization of the bone matrix contribute to the analgesic effect of zoledronic acid with respect to painful osteoblastic lesions. The agent also reduces serum calcium concentrations associated with hypercalcemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F224FB27-D55B-DD58-E040-BB89AD437691","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D574-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Vinorelbine","valueDescription":"Vinorelbine","ValueMeaning":{"publicId":"2576638","version":"1","preferredName":"Vinorelbine","longName":"2576638","preferredDefinition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle,resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinorelbine","conceptCode":"C1275","definition":"A semisynthetic vinca alkaloid. Vinorelbine binds to tubulin and prevents formation of the mitotic spindle, resulting in the arrest of tumor cell growth in metaphase. This agent may also interfere with amino acid, cyclic AMP. and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ONEDATA","dateModified":"2005-10-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D57E-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Vindesine","valueDescription":"Vindesine","ValueMeaning":{"publicId":"3380296","version":"1","preferredName":"Vindesine","longName":"3380296","preferredDefinition":"Vinblastine derivative with antineoplastic activity against acute leukemia, lung cancer, carcinoma of the breast, squamous cell carcinoma of the esophagus, head, and neck, and Hodgkin's and non-Hodgkin's lymphomas. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vindesine","conceptCode":"C934","definition":"A synthetic derivative of vinblastine, a naturally occurring vinca alkaloid. Vindesine binds to and stabilizes tubulin, thereby interrupting tubulin polymerization and preventing the formation of the mitotic spindle and cell division; treated cells are unable to undergo mitosis and are arrested in metaphase. This agent also disrupts macromolecular synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A56D-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D588-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Vincristine","valueDescription":"Vincristine","ValueMeaning":{"publicId":"3380295","version":"1","preferredName":"Vincristine","longName":"3380295","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine","conceptCode":"C933","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A54A-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D592-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Vinblastine","valueDescription":"Vinblastine","ValueMeaning":{"publicId":"3380287","version":"1","preferredName":"Vinblastine","longName":"3380287","preferredDefinition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vinblastine","conceptCode":"C930","definition":"A natural alkaloid isolated from the plant Vinca rosea Linn. Vinblastine binds to tubulin and inhibits microtubule formation, resulting in disruption of mitotic spindle assembly and arrest of tumor cells in the M phase of the cell cycle. This agent may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca++ -transport ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A492-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D59C-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Pamidronate","valueDescription":"Pamidronate","ValueMeaning":{"publicId":"4147713","version":"1","preferredName":"Pamidronate","longName":"4147713v1.00","preferredDefinition":"An amino- bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Pamidronic acid binds to and adsorbs onto hydroxyapatite crystals in the bone matrix, thereby preventing osteoclast resorption. This agent also binds to and inhibits farnesyl pyrophosphate synthase, an enzyme that plays an important role in the mevalonate pathway. This inhibits the formation of isoprenoid metabolites that are substrates for protein prenylation. This prevents farnesylation and geranylgeranylation of proteins essential for osteoclast function, leading to the induction of apoptosis of osteoclasts. By preventing osteoclast-mediated bone resorption, pamidronic acid decreases bone turnover rate, stabilizes the bone matrix and reduces hypercalcemia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamidronic Acid","conceptCode":"C61875","definition":"An amino- bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Pamidronic acid binds to and adsorbs onto hydroxyapatite crystals in the bone matrix, thereby preventing osteoclast resorption. This agent also binds to and inhibits farnesyl pyrophosphate synthase, an enzyme that plays an important role in the mevalonate pathway. This inhibits the formation of isoprenoid metabolites that are substrates for protein prenylation. This prevents farnesylation and geranylgeranylation of proteins essential for osteoclast function, leading to the induction of apoptosis of osteoclasts. By preventing osteoclast-mediated bone resorption, pamidronic acid decreases bone turnover rate, stabilizes the bone matrix and reduces hypercalcemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F224FB27-D5A6-DD58-E040-BB89AD437691","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D5BF-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Oxaliplatin","valueDescription":"Oxaliplatin","ValueMeaning":{"publicId":"2579327","version":"1","preferredName":"Oxaliplatin","longName":"2579327","preferredDefinition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oxaliplatin","conceptCode":"C1181","definition":"An organoplatinum complex in which the platinum atom is complexed with 1,2-diaminocyclohexane (DACH) and with an oxalate ligand as a 'leaving group.' A 'leaving group' is an atom or a group of atoms that is displaced as a stable species taking with it the bonding electrons. After displacement of the labile oxalate ligand leaving group, active oxaliplatin derivatives, such as monoaquo and diaquo DACH platinum, alkylate macromolecules, forming both inter- and intra-strand platinum-DNA crosslinks, which result in inhibition of DNA replication and transcription and cell-cycle nonspecific cytotoxicity. The DACH side chain appears to inhibit alkylating-agent resistance. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02EC-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D5C9-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Mitoxantrone","valueDescription":"Mitoxantrone","ValueMeaning":{"publicId":"3518877","version":"1","preferredName":"Mitoxantrone","longName":"3518877","preferredDefinition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitoxantrone","conceptCode":"C62050","definition":"An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication.  This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair.  Mitoxantrone is less cardiotoxic compared to doxorubicin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4110B19-590C-CB86-E040-BB89AD431138","latestVersionIndicator":"Yes","beginDate":"2012-07-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D5D3-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Mitomycin","valueDescription":"Mitomycin","ValueMeaning":{"publicId":"4147714","version":"1","preferredName":"Mitomycin","longName":"4147714","preferredDefinition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mitomycin","conceptCode":"C1820","definition":"A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species.  Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis.  Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F224FB27-D5DD-DD58-E040-BB89AD437691","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D5F6-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Methotrexate","valueDescription":"Methotrexate","ValueMeaning":{"publicId":"2567426","version":"1","preferredName":"Methotrexate","longName":"2567426","preferredDefinition":"An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D46F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2003-12-10","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D600-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Ixabepilone","valueDescription":"Ixabepilone","ValueMeaning":{"publicId":"3379090","version":"1","preferredName":"Ixabepilone","longName":"3379090","preferredDefinition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ixabepilone","conceptCode":"C37452","definition":"An orally bioavailable semisynthetic analogue of epothilone B with antineoplastic activity. Ixabepilone binds to tubulin and promotes tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis. This agent demonstrates antineoplastic activity against taxane-resistant cell lines.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5681-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D60A-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Ibandronate","valueDescription":"Ibandronate","ValueMeaning":{"publicId":"4147715","version":"1","preferredName":"Ibandronate","longName":"4147715v1.00","preferredDefinition":"The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibandronate Sodium","conceptCode":"C1670","definition":"The sodium salt form of ibandronic acid, a synthetic nitrogen-containing bisphosphonate. Ibandronic acid inhibits farnesyl pyrophosphate synthase, resulting in a reduction in geranylgeranyl GTPase signaling proteins and apoptosis of osteoclasts. This agent increases bone mineral density, decreases bone remodeling, inhibits osteoclast-mediated bone resorption, and reduces metastases-related and corticosteroid-related bone pain.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F224FB27-D614-DD58-E040-BB89AD437691","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D62D-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Gemcitabine","valueDescription":"Gemcitabine","ValueMeaning":{"publicId":"3145831","version":"1","preferredName":"Gemcitabine","longName":"3145831","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemcitabine","conceptCode":"C66876","definition":"A broad-spectrum antimetabolite and deoxycytidine analogue with antineoplastic activity. Upon administration, gemcitabine is converted into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP) by deoxycytidine kinase. dFdCTP competes with deoxycytidine triphosphate (dCTP) and is incorporated into DNA.  This locks DNA polymerase thereby resulting in \"masked termination\" during DNA replication. On the other hand, dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis. The reduction in the intracellular concentration of dCTP potentiates the incorporation of dFdCTP into DNA.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"91CFFC87-A1DB-4714-E040-BB89AD4352D5","latestVersionIndicator":"Yes","beginDate":"2010-10-04","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2010-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D637-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Doxorubicin Liposomal","valueDescription":"Doxorubicin Liposomal","ValueMeaning":{"publicId":"4147716","version":"1","preferredName":"Doxorubicin Liposomal","longName":"4147716","preferredDefinition":"Doxorubicin Liposomal","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F224FB27-D641-DD58-E040-BB89AD437691","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D65A-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Clodronate","valueDescription":"Clodronate","ValueMeaning":{"publicId":"4147717","version":"1","preferredName":"Clodronate","longName":"4147717v1.00","preferredDefinition":"A first-generation bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Clodronic acid adsorbs onto the surface of the hydroxyapatite crystals in bone matrix. Although the exact mechanism through which clodronic acid exerts its cytotoxic effect on osteoclasts has yet to be fully elucidated, this agent is metabolized intracellularly to a toxic beta-gamma-methylene analog of adenosine triphosphate (ATP), AppCCl2p. The ATP analog AppCCl2p competitively inhibits ADP/ATP translocase, thereby interfering with mitochondrial membrane potential and cellular energy metabolism. This may cause osteoclast apoptosis and, eventually, inhibiting osteoclast-mediated bone resorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clodronic Acid","conceptCode":"C61685","definition":"A first-generation bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Clodronic acid adsorbs onto the surface of the hydroxyapatite crystals in bone matrix. Although the exact mechanism through which clodronic acid exerts its cytotoxic effect on osteoclasts has yet to be fully elucidated, this agent is metabolized intracellularly to a toxic beta-gamma-methylene analog of adenosine triphosphate (ATP), AppCCl2p. The ATP analog AppCCl2p competitively inhibits ADP/ATP translocase, thereby interfering with mitochondrial membrane potential and cellular energy metabolism. This may cause osteoclast apoptosis and, eventually, inhibiting osteoclast-mediated bone resorption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F224FB27-D664-DD58-E040-BB89AD437691","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D67D-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Cisplatin","valueDescription":"Cisplatin","ValueMeaning":{"publicId":"3225735","version":"1","preferredName":"Cisplatin","longName":"3225735","preferredDefinition":"An inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.  In the body, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as and DNA-protein cross-links. These cisplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cisplatin","conceptCode":"C376","definition":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A041C582-8E93-4C49-E040-BB89AD434307","latestVersionIndicator":"Yes","beginDate":"2011-04-06","endDate":null,"createdBy":"WHITES","dateCreated":"2011-04-06","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D687-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Carboplatin","valueDescription":"Carboplatin","ValueMeaning":{"publicId":"3378841","version":"1","preferredName":"Carboplatin","longName":"3378841","preferredDefinition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carboplatin","conceptCode":"C1282","definition":"A second-generation platinum compound with a broad spectrum of antineoplastic properties.  Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue.  This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links.  These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition.  This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17C6-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D691-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Capecitabine","valueDescription":"CAPECITABINE","ValueMeaning":{"publicId":"2561705","version":"1","preferredName":"CAPECITABINE","longName":"2561705v1.00","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-BE16-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-07-08","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-07-08","modifiedBy":"CLOHNES","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D69B-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Alendronate","valueDescription":"Alendronate","ValueMeaning":{"publicId":"4147718","version":"1","preferredName":"Alendronate","longName":"4147718v1.00","preferredDefinition":"A second generation bisphosphonate and synthetic analog of pyrophosphate with anti-bone-resorption activity. Alendronic acid binds to and inhibits the activity of farnesyl pyrophosphate synthetase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. As a result, bone resorption and turnover are reduced.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alendronic Acid","conceptCode":"C61625","definition":"A second generation bisphosphonate and synthetic analog of pyrophosphate with anti-bone-resorption activity. Alendronic acid binds to and inhibits the activity of farnesyl pyrophosphate synthetase, an enzyme involved in terpenoid biosynthesis. Inhibition of this enzyme prevents the biosynthesis of isoprenoid lipids, donor substrates of farnesylation and geranylgeranylation during the post-translational modification of small GTPase signalling proteins, which are important in the process of osteoclast turnover. As a result, bone resorption and turnover are reduced.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F224FB27-D6A5-DD58-E040-BB89AD437691","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D6BE-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Abraxane","valueDescription":"Abraxane","ValueMeaning":{"publicId":"4147719","version":"1","preferredName":"Abraxane","longName":"4147719","preferredDefinition":"Abraxane","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F224FB27-D6C8-DD58-E040-BB89AD437691","latestVersionIndicator":"Yes","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"F224FB27-D6E1-DD58-E040-BB89AD437691","beginDate":"2014-02-11","endDate":null,"createdBy":"BASSG","dateCreated":"2014-02-11","modifiedBy":"ONEDATA","dateModified":"2014-02-11","deletedIndicator":"No"},{"value":"Blinatumomab","valueDescription":"Blinatumomab","ValueMeaning":{"publicId":"3690103","version":"1","preferredName":"Blinatumomab","longName":"3690103","preferredDefinition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blinatumomab","conceptCode":"C62528","definition":"A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D68C2697-3E36-5AFE-E040-BB89AD431E18","latestVersionIndicator":"Yes","beginDate":"2013-02-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-02-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"04DE75E5-B2CD-C2CE-E050-BB89AD4360C6","beginDate":"2014-10-07","endDate":null,"createdBy":"WANGC","dateCreated":"2014-10-07","modifiedBy":"ONEDATA","dateModified":"2014-10-07","deletedIndicator":"No"},{"value":"Tretinoin","valueDescription":"Tretinoin (ATRA)","ValueMeaning":{"publicId":"4763631","version":"1","preferredName":"Tretinoin (ATRA)","longName":"4763631","preferredDefinition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tretinoin","conceptCode":"C900","definition":"A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis.  This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types.  The oral form of tretinoin has teratogenic and embryotoxic properties.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1273ABD3-1D1F-6F1B-E050-BB89AD434A27","latestVersionIndicator":"Yes","beginDate":"2015-03-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-03-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"13106F4E-FD64-37DA-E050-BB89AD4346B4","beginDate":"2015-04-06","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-06","modifiedBy":"ONEDATA","dateModified":"2015-04-06","deletedIndicator":"No"},{"value":"Arsenic Trioxide","valueDescription":"Arsenic Trioxide","ValueMeaning":{"publicId":"3377438","version":"1","preferredName":"Arsenic Trioxide","longName":"3377438","preferredDefinition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Arsenic Trioxide","conceptCode":"C1005","definition":"A small-molecule arsenic compound with antineoplastic activity.  The mechanism of action of arsenic trioxide is not completely understood. This agent causes damage to or degradation of the promyelocytic leukemia protein/retinoic acid receptor-alpha (PML/RARa) fusion protein; induces apoptosis in acute promyelocytic leukemia (APL) cells and in many other tumor cell types; promotes cell differentiation and suppresses cell proliferation in many different tumor cell types; and is pro-angiogenic. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DF6309-A0B0-1E33-E040-BB89AD43040B","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"13106F4E-FD70-37DA-E050-BB89AD4346B4","beginDate":"2015-04-06","endDate":null,"createdBy":"WONGW","dateCreated":"2015-04-06","modifiedBy":"ONEDATA","dateModified":"2015-04-06","deletedIndicator":"No"},{"value":"Lenalidomide","valueDescription":"Lenalidomide","ValueMeaning":{"publicId":"3379210","version":"1","preferredName":"Lenalidomide","longName":"3379210","preferredDefinition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenalidomide","conceptCode":"C2668","definition":"A thalidomide analog with potential antineoplastic activity.  Lenalidomide inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), and inhibits angiogenesis.  This agent also promotes G1 cell cycle arrest and apoptosis of malignant cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B918227F-B2FA-6EA7-E040-BB89AD434A76","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B693509-8FE4-B947-E050-BB89AD43520F","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Lapatinib","valueDescription":"Lapatinib","ValueMeaning":{"publicId":"4916291","version":"1","preferredName":"Lapatinib","longName":"4916291","preferredDefinition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lapatinib","conceptCode":"C26653","definition":"A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B693509-8FEE-B947-E050-BB89AD43520F","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B693509-9008-B947-E050-BB89AD43520F","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Bevacizumab","valueDescription":"Bevacizumab","ValueMeaning":{"publicId":"4916311","version":"1","preferredName":"Bevacizumab","longName":"4916311","preferredDefinition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bevacizumab","conceptCode":"C2039","definition":"A recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine.  Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B693509-9093-B947-E050-BB89AD43520F","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B693509-90AD-B947-E050-BB89AD43520F","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Bleomycin","valueDescription":"Bleomycin","ValueMeaning":{"publicId":"2739540","version":"1","preferredName":"Bleomycin","longName":"2739540","preferredDefinition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the fungus Streptomyces verticillus.  Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bleomycin","conceptCode":"C313","definition":"A mixture of glycopeptide antineoplastic antibiotics isolated from the bacterium Streptomyces verticillus. Bleomycin forms complexes with iron that reduce molecular oxygen to superoxide and hydroxyl radicals which cause single- and double-stranded breaks in DNA; these reactive oxygen species also induce lipid peroxidation, carbohydrate oxidation, and alterations in prostaglandin synthesis and degradation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BBF7-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B693509-90BA-B947-E050-BB89AD43520F","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Carmustine","valueDescription":"Carmustine","ValueMeaning":{"publicId":"3378823","version":"1","preferredName":"Carmustine","longName":"3378823","preferredDefinition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-158F-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B693509-90D0-B947-E050-BB89AD43520F","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Isotretinoin","valueDescription":"Isotretinoin","ValueMeaning":{"publicId":"3379087","version":"1","preferredName":"Isotretinoin","longName":"3379087","preferredDefinition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Isotretinoin","conceptCode":"C603","definition":"A naturally-occurring retinoic acid with potential antineoplastic activity. Isotretinoin binds to and activates nuclear retinoic acid receptors (RARs); activated RARs serve as transcription factors that promote cell differentiation and apoptosis. This agent also exhibits immunomodulatory and anti-inflammatory responses and inhibits ornithine decarboxylase, thereby decreasing polyamine synthesis and keratinization.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B915D7F9-5638-D77C-E040-BB89AD4330BD","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B7D361F-4143-8E0C-E050-BB89AD43272E","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-22","modifiedBy":"ONEDATA","dateModified":"2015-07-22","deletedIndicator":"No"},{"value":"Cetuximab","valueDescription":"Cetuximab","ValueMeaning":{"publicId":"2574309","version":"1","preferredName":"Cetuximab","longName":"2574309","preferredDefinition":"A monoclonal antibody specific for the epidermal growth factor receptor (EGFR), a tyrosine kinase that triggers cell division.  Cetuximab binds to and inhibits EGFRs, which are overexpressed on the cell surfaces of many types of tumors.  This agent blocks the tumor growth, invasion, and metastasis associated with the overexpression of cell-surface EGFRs. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cetuximab","conceptCode":"C1723","definition":"A recombinant, chimeric monoclonal antibody directed against the epidermal growth factor (EGFR) with antineoplastic activity. Cetuximab binds to the extracellular domain of the EGFR, thereby preventing the activation and subsequent dimerization of the receptor; the decrease in receptor activation and dimerization may result in an inhibition in signal transduction and anti-proliferative effects. This agent may inhibit EGFR-dependent primary tumor growth and metastasis. EGFR is overexpressed on the cell surfaces of various solid tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EF52-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-04-02","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-04-02","modifiedBy":"REEVESD","dateModified":"2006-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B6984FD-1F0A-A790-E050-BB89AD431D19","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Cytarabine","valueDescription":"Cytarabine","ValueMeaning":{"publicId":"3270479","version":"1","preferredName":"Cytarabine","longName":"3270479","preferredDefinition":"An anticancer drug that belongs to the family of drugs called antimetabolites.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"AC7520C3-67D4-A135-E040-BB89AD436B61","latestVersionIndicator":"Yes","beginDate":"2011-09-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-09-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B6984FD-1F16-A790-E050-BB89AD431D19","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Dacarbazine","valueDescription":"Dacarbazine","ValueMeaning":{"publicId":"3378938","version":"1","preferredName":"Dacarbazine","longName":"3378938","preferredDefinition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dacarbazine","conceptCode":"C411","definition":"A triazene derivative with antineoplastic activity. Dacarbazine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B907F9D9-CD6D-F916-E040-BB89AD435222","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69AFF5-0D92-3ABA-E050-BB89AD437E3E","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Dactinomycin","valueDescription":"Dactinomycin","ValueMeaning":{"publicId":"3378914","version":"1","preferredName":"Dactinomycin","longName":"3378914","preferredDefinition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dactinomycin","conceptCode":"C412","definition":"A chromopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces parvulus.  Dactinomycin intercalates between adjacent guanine-cytosine base pairs, blocking the transcription of DNA by RNA polymerase; it also causes single-strand DNA breaks, possibly via a free-radical intermediate or an interaction with topoisomerase II. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9078B1E-F71D-89BB-E040-BB89AD432908","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69AFF5-0D9E-3ABA-E050-BB89AD437E3E","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Dexamethasone","valueDescription":"Dexamethasone","ValueMeaning":{"publicId":"3028376","version":"1","preferredName":"Dexamethasone","longName":"3028376","preferredDefinition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04) [Source: NCI]","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dexamethasone","conceptCode":"C422","definition":"A synthetic adrenal corticosteroid with potent anti-inflammatory properties. In addition to binding to specific nuclear steroid receptors, dexamethasone also interferes with NF-kB activation and apoptotic pathways. This agent lacks the salt-retaining properties of other related adrenal hormones. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8223B6A1-980B-C0E8-E040-BB89AD43538F","latestVersionIndicator":"Yes","beginDate":"2010-03-19","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-03-19","modifiedBy":"KUMMEROA","dateModified":"2022-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69AFF5-0DAA-3ABA-E050-BB89AD437E3E","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Erlotinib","valueDescription":"Erlotinib","ValueMeaning":{"publicId":"3237464","version":"1","preferredName":"Erlotinib","longName":"3237464","preferredDefinition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Erlotinib","conceptCode":"C65530","definition":"A quinazoline derivative with antineoplastic properties.  Competing with adenosine triphosphate, erlotinib reversibly binds to the intracellular catalytic domain of epidermal growth factor receptor (EGFR) tyrosine kinase, thereby reversibly inhibiting EGFR phosphorylation and blocking the signal transduction events and tumorigenic effects associated with EGFR activation.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6596-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69AFF5-0DB6-3ABA-E050-BB89AD437E3E","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Etoposide","valueDescription":"Etoposide","ValueMeaning":{"publicId":"2739535","version":"1","preferredName":"Etoposide","longName":"2739535","preferredDefinition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A728356-BAFB-71E4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"KUMMEROA","dateModified":"2022-09-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69AFF5-0DC2-3ABA-E050-BB89AD437E3E","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Gefitinib","valueDescription":"Gefitinib","ValueMeaning":{"publicId":"3237466","version":"1","preferredName":"Gefitinib","longName":"3237466","preferredDefinition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gefitinib","conceptCode":"C1855","definition":"An anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis. (NCI04)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-65BC-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69AFF5-0DCE-3ABA-E050-BB89AD437E3E","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Ifosfamide","valueDescription":"Ifosfamide","ValueMeaning":{"publicId":"2739548","version":"1","preferredName":"Ifosfamide","longName":"2739548","preferredDefinition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ifosfamide","conceptCode":"C564","definition":"A synthetic analogue of the nitrogen mustard cyclophosphamide with antineoplastic activity. Ifosfamide alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication.  This agent is a prodrug that must be activated through hydroxylation by hepatic microsomal enzymes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01A4-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69AFF5-0DDA-3ABA-E050-BB89AD437E3E","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Interleukin 2","valueDescription":"Aldesleukin","ValueMeaning":{"publicId":"2737463","version":"1","preferredName":"Aldesleukin","longName":"2737463","preferredDefinition":"A recombinant therapeutic agent which is chemically identical to or similar to the endogenous human cytokine interleukin-2 with potential antineoplastic activity.  Aldesleukin enhances lymphocyte mitogenesis, stimulates long-term growth of human IL-2 dependent cell lines, enhances lymphocyte cytotoxicity, induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities, and induces expression of interferon-gamma. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aldesleukin","conceptCode":"C1498","definition":"A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C2DF-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69AFF5-0DEF-3ABA-E050-BB89AD437E3E","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Pazopanib","valueDescription":"Pazopanib","ValueMeaning":{"publicId":"3380355","version":"1","preferredName":"Pazopanib","longName":"3380355","preferredDefinition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pazopanib","conceptCode":"C74547","definition":"A small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. Pazopanib selectively inhibits vascular endothelial growth factor receptors (VEGFR)-1, -2 and -3, c-kit and platelet derived growth factor receptor (PDGF-R), which may result in inhibition of angiogenesis in tumors in which these receptors are upregulated.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A6CA-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A01-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Prednisone","valueDescription":"Prednisone","ValueMeaning":{"publicId":"2568547","version":"1","preferredName":"Prednisone","longName":"2568547","preferredDefinition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cells populations. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prednisone","conceptCode":"C770","definition":"A synthetic glucocorticoid with anti-inflammatory and immunomodulating properties.  After cell surface receptor attachment and cell entry, prednisone enters the nucleus where it binds to and activates specific nuclear receptors, resulting in an altered gene expression and inhibition of proinflammatory cytokine production.  This agent also decreases the number of circulating lymphocytes, induces cell differentiation, and stimulates apoptosis in sensitive tumor cell populations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D8D0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"ALAIS","dateModified":"2007-02-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A0D-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Sorafenib","valueDescription":"Sorafenib","ValueMeaning":{"publicId":"3380164","version":"1","preferredName":"Sorafenib","longName":"3380164","preferredDefinition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9613-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A19-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Lomustine","valueDescription":"Lomustine","ValueMeaning":{"publicId":"2739549","version":"1","preferredName":"Lomustine","longName":"2739549","preferredDefinition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lomustine","conceptCode":"C617","definition":"A nitrosourea with antineoplastic activity. Lomustine alkylates and crosslinks DNA, thereby inhibiting DNA and RNA synthesis.  This agent also carbamoylates DNA and proteins, resulting in inhibition of DNA and RNA synthesis and disruption of RNA processing.  Lomustine is lipophilic and crosses the blood-brain barrier. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A7528ED-01D9-5EF5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A25-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"MIBG","valueDescription":"Iobenguane","ValueMeaning":{"publicId":"4916471","version":"1","preferredName":"Iobenguane","longName":"4916471","preferredDefinition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Iobenguane","conceptCode":"C87757","definition":"A synthetic, aralkylguanidine analogue of the adrenergic neurotransmitter norepinephrine (NE) and adrenergic neuron blocking agent with potential diagnostic imaging or antineoplastic activity when radiolabeled. Iobenguane, also known as metaiodobenzylguanidine (MIBG), is taken up and accumulates in the granules of adrenal medullary chromaffin cells and in the pre-synaptic granules of adrenergic neurons in a manner almost identical with that of NE. In radiolabeled forms, iobenguane may be used to image or eradicate neuroendocrine tissues and tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1B69FCD0-9A2F-6D22-E050-BB89AD433F78","latestVersionIndicator":"Yes","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A4A-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Sirolimus","valueDescription":"Sirolimus","ValueMeaning":{"publicId":"2760061","version":"1","preferredName":"Sirolimus","longName":"2760061","preferredDefinition":"A drug used to help prevent rejection of organ and bone marrow transplants by the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sirolimus","conceptCode":"C1212","definition":"A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This results in inhibition of T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (IL-2, IL-4, and IL-15) stimulation and inhibition of antibody production. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4FE455C3-3ABF-5319-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2008-06-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A56-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Vorinostat","valueDescription":"Vorinostat","ValueMeaning":{"publicId":"3380298","version":"1","preferredName":"Vorinostat","longName":"3380298","preferredDefinition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vorinostat","conceptCode":"C1796","definition":"A synthetic hydroxamic acid derivative with antineoplastic activity. Vorinostat, a second generation polar-planar compound, binds to the catalytic domain of the histone deacetylases (HDACs). This allows the hydroxamic moiety to chelate zinc ion located in the catalytic pockets of HDAC, thereby inhibiting deacetylation and leading to an accumulation of both hyperacetylated histones and transcription factors. Hyperacetylation of histone proteins results in the upregulation of the cyclin-dependant kinase p21, followed by G1 arrest. Hyperacetylation of non-histone proteins such as tumor suppressor p53, alpha tubulin, and heat-shock protein 90 produces additional anti-proliferative effects. This agent also induces apoptosis and sensitizes tumor cells to cell death processes. Vorinostat crosses the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97CA559-A5B1-BAA9-E040-BB89AD430252","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A65-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Vandetanib","valueDescription":"Vandetanib","ValueMeaning":{"publicId":"3380803","version":"1","preferredName":"Vandetanib","longName":"3380803","preferredDefinition":"An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vandetanib","conceptCode":"C2737","definition":"An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B980D66E-5D67-FB86-E040-BB89AD43770B","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A7B-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Topotecan","valueDescription":"Topotecan","ValueMeaning":{"publicId":"3380233","version":"1","preferredName":"Topotecan","longName":"3380233","preferredDefinition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Topotecan","conceptCode":"C1413","definition":"A semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata. Topotecan inhibits topoisomerase I activity by stabilizing the topoisomerase I-DNA covalent complexes during S phase of cell cycle, thereby inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing potentially lethal double-strand DNA breaks when encountered by the DNA replication machinery.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97B8401-1648-113F-E040-BB89AD431AAC","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A87-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Sunitinib","valueDescription":"Sunitinib","ValueMeaning":{"publicId":"3776074","version":"1","preferredName":"Sunitinib","longName":"3776074","preferredDefinition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sunitinib","conceptCode":"C71622","definition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DC1C-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1B69FCD0-9A93-6D22-E050-BB89AD433F78","beginDate":"2015-07-21","endDate":null,"createdBy":"TSESU","dateCreated":"2015-07-21","modifiedBy":"ONEDATA","dateModified":"2015-07-21","deletedIndicator":"No"},{"value":"Erwinase","valueDescription":"Erwinase","ValueMeaning":{"publicId":"4745495","version":"1","preferredName":"Erwinase","longName":"4745495v1.00","preferredDefinition":"An enzyme isolated from the bacterium Erwinia chrysanthemi (E. carotovora). Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting leukemic cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  This agent also induces apoptosis in tumor cells. The Erwinia-derived product is often used for those patients who have experienced a hypersensitivity reaction to the E. Coli formulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asparaginase Erwinia chrysanthemi","conceptCode":"C64260","definition":"A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"116785C4-C798-CE16-E050-BB89AD432D2C","latestVersionIndicator":"Yes","beginDate":"2015-03-16","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-03-16","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"116785C4-C7B1-CE16-E050-BB89AD432D2C","beginDate":"2015-03-16","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-03-16","modifiedBy":"ONEDATA","dateModified":"2015-03-16","deletedIndicator":"No"},{"value":"Pegaspargase","valueDescription":"Pegaspargase","ValueMeaning":{"publicId":"3379428","version":"1","preferredName":"Pegaspargase","longName":"3379428","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2066-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"116785C4-C7C5-CE16-E050-BB89AD432D2C","beginDate":"2015-03-16","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-03-16","modifiedBy":"ONEDATA","dateModified":"2015-03-16","deletedIndicator":"No"},{"value":"Denosumab","valueDescription":"Denosumab","ValueMeaning":{"publicId":"4882994","version":"1","preferredName":"Denosumab","longName":"4882994v1.00","preferredDefinition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Denosumab","conceptCode":"C61313","definition":"A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity. Denosumab specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces, resulting in inhibition of osteoclast activity, a decrease in bone resorption, and a potential increase in bone mineral density. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"18E5F18B-217C-0655-E050-BB89AD43383D","latestVersionIndicator":"Yes","beginDate":"2015-06-19","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-06-19","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"18E5F18B-2194-0655-E050-BB89AD43383D","beginDate":"2015-06-19","endDate":null,"createdBy":"MIRANDAA","dateCreated":"2015-06-19","modifiedBy":"ONEDATA","dateModified":"2015-06-19","deletedIndicator":"No"},{"value":"Azacitidine","valueDescription":"Azacitidine","ValueMeaning":{"publicId":"3013054","version":"1","preferredName":"Azacitidine","longName":"3013054","preferredDefinition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Azacitidine","conceptCode":"C288","definition":"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity. Azacitidine is incorporated into DNA, where it reversibly inhibits DNA methyltransferase, thereby blocking DNA methylation.  Hypomethylation of DNA by azacitidine may activate tumor suppressor genes silenced by hypermethylation, resulting in an antitumor effect. This agent is also incorporated into RNA, thereby disrupting normal RNA function and impairing tRNA cytosine-5-methyltransferase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7FF4D250-9950-4F75-E040-BB89AD434B4C","latestVersionIndicator":"Yes","beginDate":"2010-02-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-02-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1B43-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Bendamustine","valueDescription":"Bendamustine","ValueMeaning":{"publicId":"4862971","version":"1","preferredName":"Bendamustine","longName":"4862971","preferredDefinition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bendamustine","conceptCode":"C73261","definition":"A bifunctional mechlorethamine derivative with alkylating and antimetabolite activities. Although the exact mechanism of action of bendamustine is unknown, this agent appears to alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and eventually the induction of apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1842453B-10A4-C393-E050-BB89AD436354","latestVersionIndicator":"Yes","beginDate":"2015-06-11","endDate":null,"createdBy":"ROUILLAS","dateCreated":"2015-06-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1B4D-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Bortezomib","valueDescription":"Bortezomib","ValueMeaning":{"publicId":"2738485","version":"1","preferredName":"Bortezomib","longName":"2738485","preferredDefinition":"A modified dipeptidyl boronic acid with antineoplastic activity. Via boronic acid moiety, bortezomib reversibly binds to the 26S proteasome, where degradation of ubiquinated proteins occurs. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis.  Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Bortezomib","conceptCode":"C1851","definition":"A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F951-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1B58-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Cladribine","valueDescription":"Cladribine","ValueMeaning":{"publicId":"2829877","version":"1","preferredName":"Cladribine","longName":"2829877","preferredDefinition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cladribine","conceptCode":"C1336","definition":"A purine nucleoside antimetabolite analogue. Cladribine triphosphate, a phosphorylated metabolite of cladribine, incorporates into DNA, resulting in single-strand breaks in DNA, depletion of nicotinamide adenine dinucleotide (NAD) and adenosine triphosphate (ATP), and apoptosis.  Because this agent is resistant to adenosine deaminase, an enzyme that inactivates some antineoplastic agents, it is selectively toxic to lymphocytes and monocytes which exhibit little deoxynucleotide deaminase activity. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"617A04FE-518F-3582-E040-BB89AD432071","latestVersionIndicator":"Yes","beginDate":"2009-01-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2009-01-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1B62-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Clofarabine","valueDescription":"Clofarabine","ValueMeaning":{"publicId":"3378889","version":"1","preferredName":"Clofarabine","longName":"3378889","preferredDefinition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clofarabine","conceptCode":"C26638","definition":"A second generation purine nucleoside analog with antineoplastic activity. Clofarabine is phosphorylated intracellularly to the cytotoxic active 5'-triphosphate metabolite, which inhibits the enzymatic activities of ribonucleotide reductase and DNA polymerase, resulting in inhibition of DNA repair and synthesis of DNA and RNA. This nucleoside analog also disrupts mitochondrial function and membrane integrity, resulting in the release of pre-apoptotic factors, including cytochrome C and apoptotic-inducing factors, which activate apoptosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90729CF-408F-B0E0-E040-BB89AD436B58","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1B6C-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Daunorubicin","valueDescription":"Daunorubicin","ValueMeaning":{"publicId":"2724326","version":"1","preferredName":"Daunorubicin","longName":"2724326","preferredDefinition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daunorubicin","conceptCode":"C62091","definition":"An anthracycline antineoplastic antibiotic with therapeutic effects similar to those of doxorubicin.  Daunorubicin exhibits cytotoxic activity through topoisomerase-mediated interaction with DNA, thereby inhibiting DNA replication and repair and RNA and protein synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"443FAAF5-415D-370B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALAIS","dateCreated":"2008-01-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1B76-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Fludarabine Phosphate","valueDescription":"Fludarabine Phosphate","ValueMeaning":{"publicId":"5044412","version":"1","preferredName":"Fludarabine Phosphate","longName":"5044412","preferredDefinition":"The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fludarabine Phosphate","conceptCode":"C1102","definition":"The phosphate salt of a fluorinated nucleotide antimetabolite analog of the antiviral agent vidarabine (ara-A) with antineoplastic activity. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite may inhibit DNA polymerase alpha, ribonucleotide reductase and DNA primase, thereby interrupting DNA synthesis and inhibiting tumor cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"245B5ACF-1B83-A2B9-E050-BB89AD43722C","latestVersionIndicator":"Yes","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1B9C-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Gemtuzumab Ozogamicin","valueDescription":"Gemtuzumab Ozogamicin","ValueMeaning":{"publicId":"2741177","version":"1","preferredName":"Gemtuzumab Ozogamicin","longName":"2741177","preferredDefinition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gemtuzumab Ozogamicin","conceptCode":"C1806","definition":"A recombinant, humanized anti-CD33 monoclonal antibody attached to the cytotoxic antitumor antibiotic calicheamicin.  In this conjugate, the antibody binds to and is internalized by tumor cells expressing CD33 antigen (a sialic acid-dependent glycoprotein commonly found on the surface of leukemic blasts), thereby delivering the attached calicheamicin to CD33-expressing tumor cells. Calicheamicin binds to the minor groove of DNA, causing double strand DNA breaks and resulting in inhibition of DNA synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AE9C122-FED1-5AF3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"MAESKEB","dateModified":"2021-05-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1BA6-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Hydroxyurea","valueDescription":"Hydroxyurea","ValueMeaning":{"publicId":"2578118","version":"1","preferredName":"Hydroxyurea","longName":"2578118","preferredDefinition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hydroxyurea","conceptCode":"C560","definition":"A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle.  This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE33-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"SBREXT","dateModified":"2007-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1BB0-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Idarubicin","valueDescription":"Idarubicin","ValueMeaning":{"publicId":"2744955","version":"1","preferredName":"Idarubicin","longName":"2744955","preferredDefinition":"A semisynthetic anthracycline antineoplastic antibiotic derived from daunorubicin.  Idarubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis.  Due to its high lipophilicity, idarubicin penetrates cell membranes better than other anthracycline antibiotics.  Idarubicin hydrochloride is the therapeutic form of this drug. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idarubicin","conceptCode":"C562","definition":"A semisynthetic 4-demethoxy analogue of the antineoplastic anthracycline antibiotic daunorubicin. Idarubicin intercalates into DNA and interferes with the activity of topoisomerase II, thereby inhibiting DNA replication, RNA transcription and protein synthesis. Due to its high lipophilicity, idarubicin penetrates cell membranes more efficiently than other anthracycline antibiotic compounds.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-80C8-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1BBA-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Imatinib Mesylate","valueDescription":"Imatinib Mesylate","ValueMeaning":{"publicId":"2737465","version":"1","preferredName":"Imatinib Mesylate","longName":"2737465","preferredDefinition":"The mesylate salt of an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome.  Imatinib also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF)/c-kit; the SCF/c-kit receptor tyrosine kinase is activated in gastrointestinal stromal tumor (GIST).  This agent inhibits proliferation and induces apoptosis in cells that overexpress these oncoproteins. It is also known as Gleevec.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Imatinib Mesylate","conceptCode":"C1687","definition":"The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C337-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1BC5-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Mechlorethamine","valueDescription":"Mechlorethamine","ValueMeaning":{"publicId":"5044413","version":"1","preferredName":"Mechlorethamine","longName":"5044413","preferredDefinition":"A synthetic agent related to sulphur mustard with antineoplastic and immunosuppressive properties. Nitrogen mustard (a member of a family of chemotherapy agents including cyclophosphamide and chlorambucil) is an irritant and carcinogenic agent metabolized to a highly reactive ethylene immonium derivative; the ethylene immonium derivative alkylates DNA and inhibits DNA replication. This agent also exhibits lympholytic properties. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mechlorethamine","conceptCode":"C62056","definition":"A synthetic agent related to sulphur mustard with antineoplastic and immunosuppressive properties. Nitrogen mustard (a member of a family of chemotherapy agents including cyclophosphamide and chlorambucil) is an irritant and carcinogenic agent metabolized to a highly reactive ethylene immonium derivative; the ethylene immonium derivative alkylates DNA and inhibits DNA replication. This agent also exhibits lympholytic properties. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"245B5ACF-1BCF-A2B9-E050-BB89AD43722C","latestVersionIndicator":"Yes","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"COLBERTM","dateModified":"2023-06-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1BE8-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Mercaptopurine","valueDescription":"Mercaptopurine","ValueMeaning":{"publicId":"3379290","version":"1","preferredName":"Mercaptopurine","longName":"3379290","preferredDefinition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mercaptopurine","conceptCode":"C195","definition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B91A08CE-C80B-784E-E040-BB89AD435DD1","latestVersionIndicator":"Yes","beginDate":"2012-02-16","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-16","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1BF2-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Nelarabine","valueDescription":"Nelarabine","ValueMeaning":{"publicId":"3378092","version":"1","preferredName":"Nelarabine","longName":"3378092","preferredDefinition":"An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nelarabine","conceptCode":"C1704","definition":"An arabinonucleoside antimetabolite with antineoplastic activity. Nelarabine is demethoxylated by adenosine deaminase to become biologically active 9-beta-D-arabinosylguanine (ara-G); ara-G incorporates into DNA, thereby inhibiting DNA synthesis and inducing an S phase-dependent apoptosis of tumor cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B90208C1-35B2-0101-E040-BB89AD434367","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1C06-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Nilotinib","valueDescription":"Nilotinib","ValueMeaning":{"publicId":"2737467","version":"1","preferredName":"Nilotinib","longName":"2737467","preferredDefinition":"An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). Nilotinib interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C391-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1C10-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Procarbazine","valueDescription":"Procarbazine","ValueMeaning":{"publicId":"3379498","version":"1","preferredName":"Procarbazine","longName":"3379498","preferredDefinition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Procarbazine","conceptCode":"C62072","definition":"A methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-26E9-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1C1A-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Rituximab","valueDescription":"Rituximab","ValueMeaning":{"publicId":"2738482","version":"1","preferredName":"Rituximab","longName":"2738482","preferredDefinition":"A type of monoclonal antibody used in cancer detection or therapy. Monoclonal antibodies are laboratory-produced substances that can locate and bind to cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rituximab","conceptCode":"C1702","definition":"A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"49C0C4C2-F890-33CF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-03-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1C24-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Ruxolitinib","valueDescription":"Ruxolitinib","ValueMeaning":{"publicId":"3693066","version":"1","preferredName":"Ruxolitinib","longName":"3693066","preferredDefinition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib pecifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ruxolitinib","conceptCode":"C77888","definition":"An orally bioavailable Janus-associated kinase (JAK) inhibitor with potential antineoplastic and immunomodulating activities. Ruxolitinib specifically binds to and inhibits protein tyrosine kinases JAK 1 and 2, which may lead to a reduction in inflammation and an inhibition of cellular proliferation. The JAK-STAT (signal transducer and activator of transcription) pathway plays a key role in the signaling of many cytokines and growth factors and is involved in cellular proliferation, growth, hematopoiesis, and the immune response; JAK kinases may be upregulated in inflammatory diseases, myeloproliferative disorders, and various malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D73077EB-0B13-8CEF-E040-BB89AD43494E","latestVersionIndicator":"Yes","beginDate":"2013-03-05","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-03-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1C2E-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Thioguanine","valueDescription":"Thioguanine","ValueMeaning":{"publicId":"2744957","version":"1","preferredName":"Thioguanine","longName":"2744957","preferredDefinition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thioguanine","conceptCode":"C876","definition":"A synthetic guanosine analogue antimetabolite. Phosphorylated by hypoxanthine-guanine phosphoribosyltransferase, thioguanine incorporates into DNA and RNA, resulting in inhibition of DNA and RNA syntheses and cell death. This agent also inhibits glutamine-5-phosphoribosylpyrophosphate amidotransferase, thereby inhibiting purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BB4171E-80FC-21EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-04-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"245B5ACF-1C38-A2B9-E050-BB89AD43722C","beginDate":"2015-11-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2015-11-12","modifiedBy":"ONEDATA","dateModified":"2015-11-12","deletedIndicator":"No"},{"value":"Glembatumumab","valueDescription":"Glembatumumab","ValueMeaning":{"publicId":"5073131","version":"1","preferredName":"Glembatumumab","longName":"5073131v1.00","preferredDefinition":"A human monoclonal antibody against transmembrane glycoprotein non-metastatic melanoma protein B (GPNMB). Glembatumumab binds to GPNMB on cancer cells, but alone does not appear to inhibit cancer cell growth. However, this antibody could be utilized to deliver a conjugated cytotoxic agent to GPNMB-expressing tumor cells. GPNMB, overexpressed on the surface of various cancer cells, plays a key role in cancer cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glembatumumab","conceptCode":"C84520","definition":"A human monoclonal antibody against transmembrane glycoprotein non-metastatic melanoma protein B (GPNMB). Glembatumumab binds to GPNMB on cancer cells, but alone does not appear to inhibit cancer cell growth. However, this antibody could be utilized to deliver a conjugated cytotoxic agent to GPNMB-expressing tumor cells. GPNMB, overexpressed on the surface of various cancer cells, plays a key role in cancer cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2617DC93-8BD2-9DF5-E050-BB89AD434BBD","latestVersionIndicator":"Yes","beginDate":"2015-12-04","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-12-04","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2617DC93-8BED-9DF5-E050-BB89AD434BBD","beginDate":"2015-12-04","endDate":null,"createdBy":"DAVISJ","dateCreated":"2015-12-04","modifiedBy":"ONEDATA","dateModified":"2015-12-04","deletedIndicator":"No"},{"value":"NeuVax","valueDescription":"Nelipepimut-S","ValueMeaning":{"publicId":"5399292","version":"1","preferredName":"Nelipepimut-S","longName":"5399292","preferredDefinition":"A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nelipepimut-S","conceptCode":"C117985","definition":"A cancer vaccine comprised of a human leukocyte antigen (HLA) A2/A3 restricted HER2/neu (human epidermal growth factor receptor 2; ErbB2) nonapeptide derived from the extracellular domain of the HER2 protein, with potential immunomodulating and antineoplastic activities. Upon intradermal injection, nelipepimut-S may induce a specific cytotoxic T-lymphocyte (CTL) response against HER2/neu-expressing tumor cells. HER2/neu, a tumor-associated antigen and a member of the epidermal growth factor receptor family of tyrosine kinases, is overexpressed in various tumor cell types and plays a key role in tumorigenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"39BF2B14-36D0-FDDC-E050-BB89AD431B2B","latestVersionIndicator":"Yes","beginDate":"2016-08-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-08-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"39BF2B14-36E9-FDDC-E050-BB89AD431B2B","beginDate":"2016-08-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-08-10","modifiedBy":"ONEDATA","dateModified":"2016-08-10","deletedIndicator":"No"},{"value":"Erwinia asparaginase","valueDescription":"Erwinia asparaginase","ValueMeaning":{"publicId":"5506170","version":"1","preferredName":"Erwinia asparaginase","longName":"5506170","preferredDefinition":"Erwinia L-asparaginase is an anti-cancer chemotherapy drug.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3E35D269-F29C-59AB-E053-F662850A4126","latestVersionIndicator":"Yes","beginDate":"2016-10-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-10-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3E35D269-F2B5-59AB-E053-F662850A4126","beginDate":"2016-10-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-10-06","modifiedBy":"ONEDATA","dateModified":"2016-10-06","deletedIndicator":"No"},{"value":"Inotuzumab Ozogamicin","valueDescription":"Inotuzumab Ozogamicin","ValueMeaning":{"publicId":"5577157","version":"1","preferredName":"Inotuzumab Ozogamicin","longName":"5577157","preferredDefinition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inotuzumab Ozogamicin","conceptCode":"C71542","definition":"A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"415CA911-09D6-28BD-E053-F662850AAA2B","latestVersionIndicator":"Yes","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"415CA911-09EF-28BD-E053-F662850AAA2B","beginDate":"2016-11-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2016-11-15","modifiedBy":"ONEDATA","dateModified":"2016-11-15","deletedIndicator":"No"},{"value":"BCG","valueDescription":"BCG Vaccine","ValueMeaning":{"publicId":"5654664","version":"1","preferredName":"BCG Vaccine","longName":"5654664","preferredDefinition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BCG Vaccine","conceptCode":"C298","definition":"A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"47E22FDA-53D4-0E13-E053-F662850AD9C8","latestVersionIndicator":"Yes","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"47E22FDA-53ED-0E13-E053-F662850AD9C8","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"ONEDATA","dateModified":"2017-02-06","deletedIndicator":"No"},{"value":"Valrubicin","valueDescription":"Valrubicin","ValueMeaning":{"publicId":"4337185","version":"1","preferredName":"Valrubicin","longName":"4337185","preferredDefinition":"A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Valrubicin","conceptCode":"C1340","definition":"A semisynthetic derivative of the antineoplastic anthracycline antibiotic doxorubicin. With a mechanism of action that appears to differ from doxorubicin, valrubicin is converted intracytoplasmically into N-trifluoroacetyladriamycin, which interacts with topoisomerase II, stabilizing the complex between the enzyme and DNA; consequently, DNA replication and repair and RNA and protein synthesis are inhibited and the cell cycle is arrested in the G2 phase. In addition, this agent accumulates in the cell cytoplasm where it inhibits protein kinase C (PKC). Valrubicin is less cardiotoxic than doxorubicin when administered systemically; applied topically, this agent shows excellent tissue penetration. Structurally, the trifluoro-acetyl moiety on the amino group of the glycoside and the valerate moiety appear to result in a lipophilicity that is greater than of doxorubicin, resulting in increased intracytoplasmic concentrations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FA7C1A6F-1DB2-C2AB-E040-BB89AD436686","latestVersionIndicator":"Yes","beginDate":"2014-05-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-05-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"47E355F4-E76B-12B4-E053-F662850A1279","beginDate":"2017-02-06","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-02-06","modifiedBy":"ONEDATA","dateModified":"2017-02-06","deletedIndicator":"No"},{"value":"5-Fluorouracil (5-FU) (continuous)","valueDescription":"5-Fluorouracil (5-FU) (continuous)","ValueMeaning":{"publicId":"5978280","version":"1","preferredName":"5-Fluorouracil (5-FU) (continuous)","longName":"5978280","preferredDefinition":"5-Fluorouracil (5-FU) (continuous)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59172120-B169-3980-E053-F662850AF33C","latestVersionIndicator":"Yes","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59172120-B182-3980-E053-F662850AF33C","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"ONEDATA","dateModified":"2017-09-13","deletedIndicator":"No"},{"value":"5-Fluouracil (5-FU) (bolus)","valueDescription":"5-Fluouracil (5-FU) (bolus)","ValueMeaning":{"publicId":"5978281","version":"1","preferredName":"5-Fluouracil (5-FU) (bolus)","longName":"5978281","preferredDefinition":"5-Fluouracil (5-FU) (bolus)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59172120-B18C-3980-E053-F662850AF33C","latestVersionIndicator":"Yes","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59172120-B1A5-3980-E053-F662850AF33C","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"ONEDATA","dateModified":"2017-09-13","deletedIndicator":"No"},{"value":"Levoleucovorin","valueDescription":"Levoleucovorin","ValueMeaning":{"publicId":"5978282","version":"1","preferredName":"Levoleucovorin","longName":"5978282v1.00","preferredDefinition":"The active l-isomer of the racemic mixture of the 5-formyl derivative of tetrahydrofolic acid. Metabolically active, l-leucovorin, also known levoleucovorin, does not require bioactivation by dihydrofolate reductase, an enzyme inhibited by folic acid antagonists. This agent may enhance the effects of fluoropyrimidines by stabilizing their binding to the enzyme thymidylate synthase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levoleucovorin","conceptCode":"C1559","definition":"The active l-isomer of the racemic mixture of the 5-formyl derivative of tetrahydrofolic acid. Metabolically active, l-leucovorin, also known levoleucovorin, does not require bioactivation by dihydrofolate reductase, an enzyme inhibited by folic acid antagonists. This agent may enhance the effects of fluoropyrimidines by stabilizing their binding to the enzyme thymidylate synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59172120-B1AF-3980-E053-F662850AF33C","latestVersionIndicator":"Yes","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59172120-B1C8-3980-E053-F662850AF33C","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"ONEDATA","dateModified":"2017-09-13","deletedIndicator":"No"},{"value":"Leucovorin","valueDescription":"Leucovorin","ValueMeaning":{"publicId":"5978283","version":"1","preferredName":"Leucovorin","longName":"5978283v1.00","preferredDefinition":"A derivative of folic acid with chemoprotectant, antidote and synergistic activity. Leucovorin does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs, and is converted to a tetrahydrofolate, which is the necessary folate for purine and pyrimidine synthesis. As this agent allows for some purine/pyrimidine synthesis to occur, the toxic effects of folic acid antagonist-type chemotherapeutic drugs are counteracted while still permitting the antitumor activity of the folic acid antagonist through dihydrofolate reductase inhibition. This agent also potentiates the effects of 5-fluorouracil and its derivatives by stabilizing the binding of 5-fluorouracil's converted form fluorodeoxyuridylic acid to its target enzyme thymidylate synthase, thus prolonging drug activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leucovorin","conceptCode":"C71631","definition":"A derivative of folic acid with chemoprotectant, antidote and synergistic activity. Leucovorin does not require metabolism by dihydrofolate reductase, the molecular target of folate antagonist-type chemotherapeutic drugs, and is converted to a tetrahydrofolate, which is the necessary folate for purine and pyrimidine synthesis. As this agent allows for some purine/pyrimidine synthesis to occur, the toxic effects of folic acid antagonist-type chemotherapeutic drugs are counteracted while still permitting the antitumor activity of the folic acid antagonist through dihydrofolate reductase inhibition. This agent also potentiates the effects of 5-fluorouracil and its derivatives by stabilizing the binding of 5-fluorouracil's converted form fluorodeoxyuridylic acid to its target enzyme thymidylate synthase, thus prolonging drug activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"59172120-B1D2-3980-E053-F662850AF33C","latestVersionIndicator":"Yes","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59172120-B1EB-3980-E053-F662850AF33C","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"ONEDATA","dateModified":"2017-09-13","deletedIndicator":"No"},{"value":"Atezolizumab","valueDescription":"Atezolizumab","ValueMeaning":{"publicId":"5242662","version":"1","preferredName":"Atezolizumab","longName":"5242662","preferredDefinition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, MPDL3280A also prevents binding of this ligand to B7.1 expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of MPDL3280A is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Atezolizumab","conceptCode":"C106250","definition":"A humanized, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1; CD274), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1; PDCD1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. In addition, by binding to PD-L1, atezolizumab also prevents binding of this ligand to B7.1 (CD80) expressed on activated T cells, which further enhances the T-cell-mediated immune response. PD-L1 is overexpressed on many human cancer cell types and on various tumor-infiltrating immune cells. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in increased immune evasion. PD-1, a transmembrane protein, is a negative regulator of the immune system that limits the expansion and survival of CD8+ T cells. The Fc region of atezolizumab is modified in such a way that it does not induce either antibody-dependent cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"31F0A2DB-9907-9ED8-E050-BB89AD436E03","latestVersionIndicator":"Yes","beginDate":"2016-05-03","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-05-03","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"59172120-B1F5-3980-E053-F662850AF33C","beginDate":"2017-09-13","endDate":null,"createdBy":"SARAHB","dateCreated":"2017-09-13","modifiedBy":"ONEDATA","dateModified":"2017-09-13","deletedIndicator":"No"},{"value":"Ondansetron","valueDescription":"Ondansetron","ValueMeaning":{"publicId":"4640883","version":"1","preferredName":"Ondansetron","longName":"4640883","preferredDefinition":"A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ondansetron","conceptCode":"C1119","definition":"A carbazole derivative with antiemetic activity.  As a selective serotonin receptor antagonist, ondansetron competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-36C7-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B50088C-AB8D-295D-E053-F662850AD2BF","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","deletedIndicator":"No"},{"value":"Metoclopramide","valueDescription":"Metoclopramide","ValueMeaning":{"publicId":"6261218","version":"1","preferredName":"Metoclopramide","longName":"6261218","preferredDefinition":"A substituted benzamide and a derivative of para-aminobenzoic acid (PABA) that is structurally related to procainamide, with gastroprokinetic and antiemetic effects. Metoclopramide exerts its prokinetic effect by antagonizing dopamine mediated relaxation effect on gastrointestinal smooth muscle. This enhances the response of the gastrointestinal smooth muscle to cholinergic stimulation, thereby leading to an increase of gastric emptying into the intestines. Metoclopramide may also strengthen the lower esophagus sphincter, thereby preventing acid reflux. This agent antagonizes D2 dopamine receptors in chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metoclopramide","conceptCode":"C62046","definition":"A substituted benzamide and a derivative of para-aminobenzoic acid (PABA) that is structurally related to procainamide, with gastroprokinetic and antiemetic effects. Metoclopramide exerts its prokinetic effect by antagonizing dopamine mediated relaxation effect on gastrointestinal smooth muscle. This enhances the response of the gastrointestinal smooth muscle to cholinergic stimulation, thereby leading to an increase of gastric emptying into the intestines. Metoclopramide may also strengthen the lower esophagus sphincter, thereby preventing acid reflux. This agent antagonizes D2 dopamine receptors in chemoreceptive trigger zone (CTZ) of the medulla, thereby preventing nausea and vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B50088C-AB9A-295D-E053-F662850AD2BF","latestVersionIndicator":"Yes","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B50088C-ABB3-295D-E053-F662850AD2BF","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","deletedIndicator":"No"},{"value":"Prochlorperazine","valueDescription":"Prochlorperazine","ValueMeaning":{"publicId":"4640878","version":"1","preferredName":"Prochlorperazine","longName":"4640878","preferredDefinition":"A synthetic propylpiperazine derivative of phenothiazine with antiemetic, antipsychotic, antihistaminic, and anticholinergic activities.  Prochlorperazine antagonizes the dopamine D2-receptor in the chemoreceptor trigger zone (CTZ) of the brain and may prevent chemotherapy-induced emesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Prochlorperazine","conceptCode":"C774","definition":"A synthetic propylpiperazine derivative of phenothiazine with antiemetic, antipsychotic, antihistaminic, and anticholinergic activities.  Prochlorperazine antagonizes the dopamine D2-receptor in the chemoreceptor trigger zone (CTZ) of the brain and may prevent chemotherapy-induced emesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0A7E4D2D-3656-F298-E050-BB89AD4309D6","latestVersionIndicator":"Yes","beginDate":"2014-12-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-12-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B50088C-ABBD-295D-E053-F662850AD2BF","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","deletedIndicator":"No"},{"value":"Dronabinol","valueDescription":"Dronabinol","ValueMeaning":{"publicId":"2576799","version":"1","preferredName":"Dronabinol","longName":"2576799","preferredDefinition":"A synthetic form of delta-9-tetrahydrocannabinol, a psychoactive substance found in Cannabis sativa.  Dronabinol acts directly on the appetite and vomiting control centers in the brain to stimulate appetite and prevent emesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dronabinol","conceptCode":"C867","definition":"An isomer of tetrahydrocannabinol (THC) that is the main and most active isomer found in the Cannabis sativa L. plant, with potential anti-emetic, analgesic and appetite stimulating activities. Upon administration, dronabinol, also called delta-9-THC, targets and binds to cannabinoid receptors (CBRs) located in the central nervous system (CNS). Dronabinol acts directly on the appetite and vomiting control centers in the brain to stimulate appetite and prevent emesis. In addition, this agent induces analgesia. Urine levels may be used as a marker to determine the exposure to certain preparations containing parts of the cannabis plant, such as marijuana.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F90C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-07","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B50088C-ABC7-295D-E053-F662850AD2BF","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","deletedIndicator":"No"},{"value":"Haloperidol","valueDescription":"Haloperidol","ValueMeaning":{"publicId":"2578111","version":"1","preferredName":"Haloperidol","longName":"2578111","preferredDefinition":"A drug that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorder, ballism, and Tourette's syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of Huntington's disease. It is a potent antiemetic and is effective in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Haloperidol","conceptCode":"C537","definition":"A phenylbutylpiperadine derivative with antipsychotic, neuroleptic, and antiemetic activities. Haloperidol competitively blocks postsynaptic dopamine (D2) receptors in the mesolimbic system of the brain, thereby eliminating dopamine neurotransmission and leading to antidelusionary and antihallucinagenic effects. Antagonistic activity mediated through D2 dopamine receptors in the chemoreceptive trigger zone (CTZ) accounts for its antiemetic activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE2C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-06","modifiedBy":"ONEDATA","dateModified":"2006-03-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B50088C-ABD2-295D-E053-F662850AD2BF","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","deletedIndicator":"No"},{"value":"Lorazepam","valueDescription":"Lorazepam","ValueMeaning":{"publicId":"2578244","version":"1","preferredName":"Lorazepam","longName":"2578244","preferredDefinition":"An anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lorazepam","conceptCode":"C619","definition":"A benzodiazepine with anxiolytic, anti-anxiety, anticonvulsant, anti-emetic and sedative properties. Lorazepam enhances the effect of the inhibitory neurotransmitter gamma-aminobutyric acid on the GABA receptors by binding to a site that is distinct from the GABA binding site in the central nervous system. This leads to an increase in chloride channel opening events, a facilitation of chloride ion conductance, membrane hyperpolarization, and eventually inhibition of the transmission of nerve signals, thereby decreasing nervous excitation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FEB1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B50088C-ABDC-295D-E053-F662850AD2BF","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","deletedIndicator":"No"},{"value":"Diphenhydramine","valueDescription":"Diphenhydramine","ValueMeaning":{"publicId":"6261220","version":"1","preferredName":"Diphenhydramine","longName":"6261220","preferredDefinition":"A first generation antihistamine and ethanolamine with sedative and anti-allergic properties. Diphenhydramine competitively inhibits the histamine-1 (H1) receptor, thereby alleviating the symptoms caused by endogenous histamine on bronchial, capillary and gastrointestinal smooth muscles. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diphenhydramine","conceptCode":"C61728","definition":"A first generation antihistamine and ethanolamine with sedative and anti-allergic properties. Diphenhydramine competitively inhibits the histamine-1 (H1) receptor, thereby alleviating the symptoms caused by endogenous histamine on bronchial, capillary and gastrointestinal smooth muscles. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B50088C-ABE9-295D-E053-F662850AD2BF","latestVersionIndicator":"Yes","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B50088C-AC02-295D-E053-F662850AD2BF","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","deletedIndicator":"No"},{"value":"Anticholinergics: Scopolamine transdermal patch","valueDescription":"Anticholinergic Agent Scopolamine Skin Patch Dosage Form","ValueMeaning":{"publicId":"6261224","version":"1","preferredName":"Anticholinergic Agent Scopolamine Skin Patch Dosage Form","longName":"6261224","preferredDefinition":"Any agent that binds to and blocks nicotinic and/or muscarinic receptors, thereby preventing the actions of the neurotransmitter acetylcholine (Ach) at these receptors.: A tropane alkaloid derived from plants of the nightshade family (Solanaceae), specifically Hyoscyamus niger and Atropa belladonna, with anticholinergic, antiemetic and antivertigo properties. Structurally similar to acetylcholine, scopolamine antagonizes acetylcholine activity mediated by muscarinic receptors located on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. The agent is used to cause mydriasis, cycloplegia, to control the secretion of saliva and gastric acid, to slow gut motility, and prevent vomiting.: A patch intended for administration to the skin.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Anticholinergic Agent","conceptCode":"C66880","definition":"Any agent that binds to and blocks nicotinic and/or muscarinic receptors, thereby preventing the actions of the neurotransmitter acetylcholine (Ach) at these receptors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Scopolamine","conceptCode":"C47712","definition":"A tropane alkaloid derived from plants of the nightshade family (Solanaceae), specifically Hyoscyamus niger and Atropa belladonna, with anticholinergic, antiemetic and antivertigo properties. Structurally similar to acetylcholine, scopolamine antagonizes acetylcholine activity mediated by muscarinic receptors located on structures innervated by postganglionic cholinergic nerves as well as on smooth muscles that respond to acetylcholine but lack cholinergic innervation. The agent is used to cause mydriasis, cycloplegia, to control the secretion of saliva and gastric acid, to slow gut motility, and prevent vomiting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Skin Patch Dosage Form","conceptCode":"C28276","definition":"A patch intended for administration to the skin.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6B50088C-AC13-295D-E053-F662850AD2BF","latestVersionIndicator":"Yes","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6B50088C-AC2C-295D-E053-F662850AD2BF","beginDate":"2018-05-03","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-05-03","modifiedBy":"ONEDATA","dateModified":"2018-05-03","deletedIndicator":"No"},{"value":"6-mercaptopurine","valueDescription":"Six Mercaptopurine","ValueMeaning":{"publicId":"6346910","version":"1","preferredName":"Six Mercaptopurine","longName":"6346910","preferredDefinition":"A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.: A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Six","conceptCode":"C66837","definition":"A natural number greater than 5 and less than 7 and the quantity that it denotes: the sum of five and one.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mercaptopurine","conceptCode":"C195","definition":"A thiopurine-derivative antimetabolite with antineoplastic and immunosuppressive activities.  Produced through the metabolism of mercaptopurine by hypoxanthine-guanine phosphoribosyltransferase (HGPRT), mercaptopurine metabolites 6-thioguanosine-5'-phosphate (6-thioGMP) and 6-thioinosine monophosphate (T-IMP) inhibit nucleotide interconversions and de novo purine synthesis, thereby blocking the formation of purine nucleotides and inhibiting DNA synthesis.  This agent is also incorporated into DNA in the form of deoxythioguanosine, which results in the disruption of DNA replication. In addition, mercaptopurine is converted to 6-methylmercaptopurine ribonucleoside (MMPR) by 6-thiopurine methyltransferase; MMPRs are also potent inhibitors of de novo purine synthesis. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"70913F9F-D339-222C-E053-F662850A4C14","latestVersionIndicator":"Yes","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"70913F9F-D352-222C-E053-F662850A4C14","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"},{"value":"Leukapheresis","valueDescription":"Leukapheresis","ValueMeaning":{"publicId":"2579318","version":"1","preferredName":"Leukapheresis","longName":"2579318","preferredDefinition":"Removal of the blood to collect specific blood cells; the remaining blood is returned to the body.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukapheresis","conceptCode":"C15269","definition":"A procedure that collects white blood cells from the peripheral blood while returning the rest to the donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-02E3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-05-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-05-18","modifiedBy":"KUMMEROA","dateModified":"2023-08-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"70913F9F-D35C-222C-E053-F662850A4C14","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"},{"value":"Corticosteroids","valueDescription":"Corticosteroid","ValueMeaning":{"publicId":"3951357","version":"1","preferredName":"Corticosteroid","longName":"3951357","preferredDefinition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).(NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Corticosteroid","conceptCode":"C2322","definition":"Hormones synthesized in the cortex of the adrenal gland and consist of two subclasses, glucocorticoids (carbohydrate regulation) and mineralocorticoids (electrolyte regulation).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EAE91AA1-BCFE-7D56-E040-BB89AD4361DC","latestVersionIndicator":"Yes","beginDate":"2013-11-11","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"70913F9F-D371-222C-E053-F662850A4C14","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"},{"value":"Intrathecal chemotherapy","valueDescription":"Intrathecal Chemotherapy","ValueMeaning":{"publicId":"5143296","version":"1","preferredName":"Intrathecal Chemotherapy","longName":"5143296","preferredDefinition":"Treatment in which anticancer drugs are injected into the fluid-filled space between the thin layers of tissue that cover the brain and spinal cord.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intrathecal Chemotherapy","conceptCode":"C15750","definition":"Chemotherapy delivered via the spinal canal.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2CB1C481-C5A4-1475-E050-BB89AD433B19","latestVersionIndicator":"Yes","beginDate":"2016-02-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-02-26","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"70913F9F-D386-222C-E053-F662850A4C14","beginDate":"2018-07-09","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-07-09","modifiedBy":"ONEDATA","dateModified":"2018-07-09","deletedIndicator":"No"},{"value":"Entrectinib","valueDescription":"Entrectinib","ValueMeaning":{"publicId":"6617876","version":"1","preferredName":"Entrectinib","longName":"6617876","preferredDefinition":"An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Entrectinib","conceptCode":"C114984","definition":"An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"800F9D7B-55F3-37F4-E053-F662850ADFFC","latestVersionIndicator":"Yes","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"800F9D7B-560C-37F4-E053-F662850ADFFC","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"ONEDATA","dateModified":"2019-01-22","deletedIndicator":"No"},{"value":"GDC-0084","valueDescription":"PI3K Inhibitor GDC-0084","ValueMeaning":{"publicId":"6617877","version":"1","preferredName":"PI3K Inhibitor GDC-0084","longName":"6617877","preferredDefinition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor GDC-0084 specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Paxalisib","conceptCode":"C116877","definition":"A phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. paxalisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in the inhibition of both cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"800F9D7B-5618-37F4-E053-F662850ADFFC","latestVersionIndicator":"Yes","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"ONEDATA","dateModified":"2019-01-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"800F9D7B-5631-37F4-E053-F662850ADFFC","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"ONEDATA","dateModified":"2019-01-22","deletedIndicator":"No"},{"value":"Abemaciclib","valueDescription":"Abemaciclib","ValueMeaning":{"publicId":"6148605","version":"1","preferredName":"Abemaciclib","longName":"6148605","preferredDefinition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Abemaciclib","conceptCode":"C97660","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of the serine/threonine kinases CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"682DF2C6-77AE-47D7-E053-F662850A61D2","latestVersionIndicator":"Yes","beginDate":"2018-03-24","endDate":null,"createdBy":"TAYLORT","dateCreated":"2018-03-24","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"800F9D7B-5645-37F4-E053-F662850ADFFC","beginDate":"2019-01-22","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-22","modifiedBy":"ONEDATA","dateModified":"2019-01-22","deletedIndicator":"No"},{"value":"Watch and wait","valueDescription":"Active Surveillance","ValueMeaning":{"publicId":"6034921","version":"1","preferredName":"Active Surveillance","longName":"6034921","preferredDefinition":"Closely watching a patient's condition but not giving treatment unless there are changes in test results. Active surveillance avoids problems that may be caused by treatments such as radiation or surgery. It is used to find early signs that the condition is getting worse. During active surveillance, patients will be given certain exams and tests done on a regular schedule. It is sometimes used in prostate cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient Observation","conceptCode":"C15722","definition":"Closely watching a patient's condition but not giving treatment unless there are changes in test results. Active surveillance avoids problems that may be caused by treatments such as radiation or surgery. It is used to find early signs that the condition is getting worse. During active surveillance, patients will be given certain exams and tests done on a regular schedule. It is sometimes used in prostate cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5F27EEFA-40BA-2FF7-E053-F662850A3F82","latestVersionIndicator":"Yes","beginDate":"2017-11-29","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-11-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A790-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Thalidomide","valueDescription":"Thalidomide","ValueMeaning":{"publicId":"2568117","version":"1","preferredName":"Thalidomide","longName":"2568117","preferredDefinition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thalidomide","conceptCode":"C870","definition":"A synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties.  Thalidomide acts primarily by inhibiting both the production of tumor necrosis factor alpha (TNF-alpha) in stimulated peripheral monocytes and the activities of interleukins and interferons.  This agent also inhibits polymorphonuclear chemotaxis and monocyte phagocytosis.  In addition, thalidomide inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), thereby inhibiting angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D722-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-01-26","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-01-26","modifiedBy":"REEVESD","dateModified":"2016-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A79A-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Stem Cell Transplant","valueDescription":"Hematopoietic Cell Transplantation","ValueMeaning":{"publicId":"4395931","version":"1","preferredName":"Hematopoietic Cell Transplantation","longName":"4395931","preferredDefinition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hematopoietic Cell Transplantation","conceptCode":"C15431","definition":"A therapeutic procedure that involves the transplantation of hematopoietic stem cells, either with the patient as their own donor or from a donor to a patient. This can be used for treatment of malignant and non-malignant diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FEBB1E93-3F07-E882-E040-BB89AD431336","latestVersionIndicator":"Yes","beginDate":"2014-07-21","endDate":null,"createdBy":"COOPERM","dateCreated":"2014-07-21","modifiedBy":"MMADDINENI","dateModified":"2024-02-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A7A4-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Pomalidomide","valueDescription":"Pomalidomide","ValueMeaning":{"publicId":"3944871","version":"1","preferredName":"Pomalidomide","longName":"3944871","preferredDefinition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pomalidomide","conceptCode":"C72560","definition":"An orally bioavailable derivative of thalidomide with potential immunomodulating, antiangiogenic and antineoplastic activities. Although its exact mechanism of action has yet to be fully elucidated, pomalidomide appears to inhibit TNF-alpha production, enhance the activity of T cells and natural killer (NK) cells and enhance antibody-dependent cellular cytotoxicity (ADCC). In addition, pomalidomide may inhibit tumor angiogenesis, promote cell cycle arrest in susceptible tumor cell populations, and stimulate erythropoeisis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA60336B-F055-AE12-E040-BB89AD435C63","latestVersionIndicator":"Yes","beginDate":"2013-11-04","endDate":null,"createdBy":"REEVESD","dateCreated":"2013-11-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A7AE-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Plerixafor","valueDescription":"Plerixafor","ValueMeaning":{"publicId":"3631680","version":"1","preferredName":"Plerixafor","longName":"3631680","preferredDefinition":"A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plerixafor","conceptCode":"C1777","definition":"A bicyclam with hematopoietic stem cell-mobilizing activity. Plerixafor blocks the binding of stromal cell-derived factor (SDF-1alpha) to the cellular receptor CXCR4, resulting in hematopoietic stem cell (HSC) release from bone marrow and HSC movement into the peripheral circulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CFB802C2-BC50-449B-E040-BB89AD4358D4","latestVersionIndicator":"Yes","beginDate":"2012-11-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-11-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A7B8-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Plasmapheresis","valueDescription":"Plasmapheresis","ValueMeaning":{"publicId":"6159897","version":"1","preferredName":"Plasmapheresis","longName":"6159897","preferredDefinition":"The process of separating certain cells from the plasma in the blood by a machine; only the cells are returned to the person. Plasmapheresis can be used to remove excess antibodies from the blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasmapheresis","conceptCode":"C15304","definition":"A procedure that collects plasma from the peripheral blood while returning the rest to the donor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AD6E55-A8BE-3C96-E053-F662850A17E8","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A7C2-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Panobinostat","valueDescription":"Panobinostat","ValueMeaning":{"publicId":"3379455","version":"1","preferredName":"Panobinostat","longName":"3379455","preferredDefinition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Panobinostat","conceptCode":"C66948","definition":"A cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein expression, cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the expression of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2334-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A7CC-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Pamidronate Disodium","valueDescription":"Pamidronate Disodium","ValueMeaning":{"publicId":"2576642","version":"1","preferredName":"Pamidronate Disodium","longName":"2576642","preferredDefinition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pamidronate Disodium","conceptCode":"C1345","definition":"The disodium salt of the synthetic bisphosphonate pamidronate. Although its mechanism of action is not completely understood, pamidronate appears to adsorb to calcium phosphate crystals in bone, blocking their dissolution by inhibiting osteoclast-mediated bone resorption. This agent does not inhibit bone mineralization and formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F86F-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-10-18","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A7D6-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Melphalan Hydrochloride","valueDescription":"Melphalan Hydrochloride","ValueMeaning":{"publicId":"6592216","version":"1","preferredName":"Melphalan Hydrochloride","longName":"6592216","preferredDefinition":"A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Melphalan Hydrochloride","conceptCode":"C48002","definition":"A bifunctional alkylating agent and phenylalanine derivative of nitrogen mustard. Melphalan hydrochloride is converted into highly reactive ethylenimmonium intermediates that induce covalent guanine N7-N7 intra- and inter-crosslinks and alkylation of adenine N3 of DNA. This agent also alkylates RNA and protein structures. As a result RNA transcription and protein synthesis are inhibited, ultimately leading to cell growth arrest and/or death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7D384416-6457-1487-E053-F662850AF67B","latestVersionIndicator":"Yes","beginDate":"2018-12-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-12-17","modifiedBy":"ONEDATA","dateModified":"2018-12-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A7EA-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Ixazomib Citrate","valueDescription":"Ixazomib Citrate","ValueMeaning":{"publicId":"6025022","version":"1","preferredName":"Ixazomib Citrate","longName":"6025022","preferredDefinition":"The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ixazomib Citrate","conceptCode":"C82653","definition":"The citrate salt form of ixazomib, an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. Ixazomib inhibits the activity of the proteasome, blocking the targeted proteolysis normally performed by the proteasome, which results in an accumulation of unwanted or misfolded proteins; disruption of various cell signaling pathways may follow, resulting in the induction of apoptosis. Compared to first generation PIs, second generation PIs may have an improved pharmacokinetic profile with increased potency and less toxicity. Proteasomes are large protease complexes that degrade unneeded or damaged proteins that have been ubiquinated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5D64DFD7-C3D9-166D-E053-F662850A1FF3","latestVersionIndicator":"Yes","beginDate":"2017-11-07","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-11-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE131D6-A7FE-6AA6-E053-F662850A7FD1","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Intravenous immunoglobulin","valueDescription":"Intravenous Immunoglobulin Therapy","ValueMeaning":{"publicId":"6051439","version":"1","preferredName":"Intravenous Immunoglobulin Therapy","longName":"6051439","preferredDefinition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Immunoglobulin Therapy","conceptCode":"C121331","definition":"The administration of a blood product derived from pooled IgG antibodies extracted from donor plasma delivered intravenously. It is used to treat multiple disorders, including immunodeficiencies, autoimmune disorders, and active infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"62E6E09D-AF1C-7E3A-E053-F662850A049D","latestVersionIndicator":"Yes","beginDate":"2018-01-16","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-01-16","modifiedBy":"KUMMEROA","dateModified":"2023-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE04791-8224-63CD-E053-F662850A190D","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Elotuzumab","valueDescription":"Elotuzumab","ValueMeaning":{"publicId":"5621728","version":"1","preferredName":"Elotuzumab","longName":"5621728","preferredDefinition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Elotuzumab","conceptCode":"C66982","definition":"A humanized monoclonal antibody directed against the human CS1 (CD2 subset 1, CRACC, SLAMF7) antigen with potential antineoplastic activity. Elotuzumab binds to the CS1 antigen, which may trigger antibody-dependent cellular cytotoxicity (ADCC) in cells expressing CS1. CS1 is a cell surface glycoprotein belonging to the CD2 subset of the immunoglobulin superfamily (IgSF) and is highly expressed by multiple myeloma cells, but minimally expressed by normal cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC55-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE04791-822E-63CD-E053-F662850A190D","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Donor lymphocyte infusion","valueDescription":"Donor Leukocyte Infusion","ValueMeaning":{"publicId":"2866902","version":"1","preferredName":"Donor Leukocyte Infusion","longName":"2866902","preferredDefinition":"A type of therapy in which lymphocytes from the blood of a donor are given to a patient who has already received a stem cell transplant from the same donor. The donor lymphocytes may kill remaining cancer cells. Donor lymphocyte infusion is used to treat chronic myelogenous leukemia (CML) that has come back and myeloma. It is being studied in the treatment of other types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Donor Lymphocyte Infusion","conceptCode":"C16145","definition":"The infusion of donor lymphocytes following hematopoietic stem cell transplantation for the purpose of augmenting the host immune response or preventing the rejection of the graft.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68DF7602-9A6D-3F9A-E040-BB89AD43599F","latestVersionIndicator":"Yes","beginDate":"2009-05-01","endDate":null,"createdBy":"CZECHS","dateCreated":"2009-05-01","modifiedBy":"KUMMEROA","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE04791-8242-63CD-E053-F662850A190D","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Daratumumab","valueDescription":"Daratumumab","ValueMeaning":{"publicId":"5621727","version":"1","preferredName":"Daratumumab","longName":"5621727","preferredDefinition":"A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Daratumumab","conceptCode":"C74007","definition":"A human immunoglobulin G1-kappa (IgG1k) monoclonal antibody directed against the cell surface glycoprotein CD38, with immunomodulating and antineoplastic activities. Upon administration, daratumumab targets and binds to CD38 expressed on tumor cells. This triggers direct cell killing, antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cell mediated phagocytosis (ADCP) and antibody-mediated complement dependent cytotoxicity (CDC) in CD38-expressing tumor cells. In addition, binding to CD38 by daratumumab depletes CD38-expressing immunosuppressive regulatory T- and B-cells and myeloid-derived suppressor cells (MDSCs). CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"45AECAE5-BC32-28A7-E053-F662850AD609","latestVersionIndicator":"Yes","beginDate":"2017-01-09","endDate":null,"createdBy":"REEVESD","dateCreated":"2017-01-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE04791-824C-63CD-E053-F662850A190D","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Complementary/alternative medicine","valueDescription":"Complementary and Alternate medicine","ValueMeaning":{"publicId":"4163033","version":"1","preferredName":"Complementary and Alternate medicine","longName":"4163033","preferredDefinition":"Forms of treatment that are used in addition to (complementary) or instead of (alternative) standard treatments. These practices generally are not considered standard medical approaches. Standard treatments go through a long and careful research process to prove they are safe and effective, but less is known about most types of CAM. CAM may include dietary supplements, megadose vitamins, herbal preparations, special teas, acupuncture, massage therapy, magnet therapy, spiritual healing, and meditation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complementary and Alternative Medicine","conceptCode":"C15178","definition":"A group of diverse medical and health care systems, practices, and products that are not presently considered to be part of conventional medicine. Complementary medicine as being used together with conventional medicine, whereas alternative medicine is used in place of conventional medicine. The National Center for Complementary and Alternative Medicine (NCCAM) groups CAM practices into four domains, recognizing there can be some overlap: mind-body medicine; biologically based practices, manipulative and body-based practices, and energy medicine. In addition, NCCAM studies CAM whole medical systems, which cut across all domains.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F2B66760-38BB-D9B8-E040-BB89AD435A64","latestVersionIndicator":"Yes","beginDate":"2014-02-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-02-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE04791-8260-63CD-E053-F662850A190D","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Carfilzomib","valueDescription":"Carfilzomib","ValueMeaning":{"publicId":"3378843","version":"1","preferredName":"Carfilzomib","longName":"3378843","preferredDefinition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carfilzomib","conceptCode":"C52196","definition":"An epoxomicin derivate with potential antineoplastic activity. Carfilzomib irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S catalytic core subunit of the proteasome, a protease complex responsible for degrading a large variety of cellular proteins. Inhibition of proteasome-mediated proteolysis results in an accumulation of polyubiquinated proteins, which may lead to cell cycle arrest, induction of apoptosis, and inhibition of tumor growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B906B2BD-17EC-3273-E040-BB89AD431F7C","latestVersionIndicator":"Yes","beginDate":"2012-02-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE04791-826A-63CD-E053-F662850A190D","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Idelalsib","valueDescription":"Idelalisib","ValueMeaning":{"publicId":"5096863","version":"1","preferredName":"Idelalisib","longName":"5096863","preferredDefinition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Idelalisib","conceptCode":"C78825","definition":"An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities.  Idelalisib inhibits the production of the second messenger phosphatidylinositol-3,4,5-trisphosphate (PIP3), preventing the activation of the PI3K signaling pathway and inhibiting tumor cell proliferation, motility, and survival. Unlike other isoforms of PI3K, PI3K-delta is expressed primarily in hematopoietic lineages. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28ACEAFB-479D-6667-E050-BB89AD432DA7","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE38C99-7C4A-1BD4-E053-F662850AA965","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Ibrutinib","valueDescription":"Ibrutinib","ValueMeaning":{"publicId":"5588944","version":"1","preferredName":"Ibrutinib","longName":"5588944","preferredDefinition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ibrutinib","conceptCode":"C81934","definition":"An orally bioavailable, small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon oral administration, ibrutinib binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is required for B cell receptor signaling, plays a key role in B-cell maturation, and is overexpressed in a number of B-cell malignancies. The expression of BTK in tumor cells is also associated with increased proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"42B08557-93BA-6CD6-E053-F662850A558E","latestVersionIndicator":"Yes","beginDate":"2016-12-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-12-02","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE38C99-7C54-1BD4-E053-F662850AA965","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Chlorambucil","valueDescription":"Chlorambucil","ValueMeaning":{"publicId":"2577804","version":"1","preferredName":"Chlorambucil","longName":"2577804","preferredDefinition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chlorambucil","conceptCode":"C362","definition":"An orally-active antineoplastic aromatic nitrogen mustard. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCF9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-02-24","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-02-24","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE38C99-7C5E-1BD4-E053-F662850AA965","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Alemtuzumab","valueDescription":"Alemtuzumab","ValueMeaning":{"publicId":"2577772","version":"1","preferredName":"Alemtuzumab","longName":"2577772","preferredDefinition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alemtuzumab","conceptCode":"C1681","definition":"A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human variable framework and constant regions, and complementarity-determining regions derived from a rat monoclonal antibody. This agent selectively binds to CD52, thereby triggering a host immune response that results in lysis of CD52 + cells. CD52 is a glycoprotein expressed on the surface of essentially all normal and malignant B and T cells, a majority of monocytes, macrophages and natural killer (NK) cells, a subpopulation of granulocytes, and tissues of the male reproductive system. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FCD9-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-20","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-20","modifiedBy":"ALEYR","dateModified":"2008-04-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE38C99-7C68-1BD4-E053-F662850AA965","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Vincristine sulfate","valueDescription":"Vincristine Sulfate","ValueMeaning":{"publicId":"6159977","version":"1","preferredName":"Vincristine Sulfate","longName":"6159977","preferredDefinition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vincristine Sulfate","conceptCode":"C1739","definition":"The sulfate salt of a natural alkaloid isolated from the plant Catharanthus roseus (Vinca rosea L.) with antimitotic and antineoplastic activities. Vincristine binds irreversibly to microtubules and spindle proteins in S phase of the cell cycle and interferes with the formation of the mitotic spindle, thereby arresting tumor cells in metaphase. This agent also depolymerizes microtubules and may also interfere with amino acid, cyclic AMP, and glutathione metabolism; calmodulin-dependent Ca(2+)-activated ATPase activity; cellular respiration; and nucleic acid and lipid biosynthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D64A63-4CB5-54A6-E053-F662850A6CA8","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE3E4A7-CE4E-41D1-E053-F662850AD488","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Venetoclax","valueDescription":"Venetoclax","ValueMeaning":{"publicId":"5944045","version":"1","preferredName":"Venetoclax","longName":"5944045","preferredDefinition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Venetoclax","conceptCode":"C103147","definition":"An orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. Venetoclax mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells. Bcl-2 protein is overexpressed in some cancers and plays an important role in the regulation of apoptosis; its expression is associated with increased drug resistance and tumor cell survival. Compared to the Bcl-2 inhibitor navitoclax, this agent does not inhibit bcl-XL and does not cause bcl-XL-mediated thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"57E65346-8D8B-6C22-E053-F662850A5722","latestVersionIndicator":"Yes","beginDate":"2017-08-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE3E4A7-CE58-41D1-E053-F662850AD488","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Pentostatin","valueDescription":"Pentostatin","ValueMeaning":{"publicId":"5127413","version":"1","preferredName":"Pentostatin","longName":"5127413","preferredDefinition":"The active ingredient in a drug that is used to treat hairy cell leukemia and is being studied in the treatment of other types of cancer. Pentostatin blocks a protein needed for cell growth and may kill cancer cells. It is made by a bacterium. It is a type of adenosine deaminase inhibitor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pentostatin","conceptCode":"C732","definition":"A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2C5DDD88-FAA7-F93D-E050-BB89AD437D4E","latestVersionIndicator":"Yes","beginDate":"2016-02-22","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2016-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE3E4A7-CE62-41D1-E053-F662850AD488","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Ofatumumab","valueDescription":"Ofatumumab","ValueMeaning":{"publicId":"3243442","version":"1","preferredName":"Ofatumumab","longName":"3243442","preferredDefinition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ofatumumab","conceptCode":"C66952","definition":"A fully human, high-affinity IgG1 monoclonal antibody directed against the B cell CD20 cell surface antigen with potential antineoplastic activity. Ofatumumab binds specifically to CD20 on the surfaces of B cells, triggering complement-dependent cell lysis (CDCL) and antibody-dependent cell-mediated cytotoxicity (ADCC) of B cells overexpressing CD20. The CD20 antigen, found on over 90% of B cells, B cell lymphomas, and other B cells of lymphoid tumors of B cell origin, is a non-glycosylated cell surface phosphoprotein that acts as a calcium ion channel; it is exclusively expressed on B cells during most stages of B cell development.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A55A32E7-3256-D7C0-E040-BB89AD437508","latestVersionIndicator":"Yes","beginDate":"2011-06-10","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-06-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE3E4A7-CE6C-41D1-E053-F662850AD488","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Obinutuzumab","valueDescription":"Obinutuzumab","ValueMeaning":{"publicId":"5096860","version":"1","preferredName":"Obinutuzumab","longName":"5096860","preferredDefinition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Afutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Obinutuzumab","conceptCode":"C70741","definition":"A glycoengineered, humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B cells. The Fc region carbohydrates of the antibody, enriched in bisected non-fucosylated glycosylation variants, contribute to its higher binding affinity for human FcgammaRIII receptors compared to non-glycoengineered antibodies, resulting in enhanced antibody-dependent cellular cytotoxicity (ADCC) and caspase-independent apoptosis. In addition, modification of elbow hinge sequences within the antibody variable framework regions may account for the strong apoptosis-inducing activity of R7159 upon binding to CD20 on target cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28ACEAFB-4750-6667-E050-BB89AD432DA7","latestVersionIndicator":"Yes","beginDate":"2016-01-06","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE3E4A7-CE76-41D1-E053-F662850AD488","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Methylprednisolone acetate","valueDescription":"Methylprednisolone Acetate","ValueMeaning":{"publicId":"6606398","version":"1","preferredName":"Methylprednisolone Acetate","longName":"6606398","preferredDefinition":"The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone Acetate","conceptCode":"C48003","definition":"The acetate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and antiinflammatory effects. Methylprednisolone acetate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7EE3E4A7-CE83-41D1-E053-F662850AD488","latestVersionIndicator":"Yes","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE3E4A7-CE9C-41D1-E053-F662850AD488","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Methylprednisolone sodium succinate","valueDescription":"Methylprednisolone Sodium Succinate","ValueMeaning":{"publicId":"6159937","version":"1","preferredName":"Methylprednisolone Sodium Succinate","longName":"6159937","preferredDefinition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Methylprednisolone Sodium Succinate","conceptCode":"C48004","definition":"The sodium succinate salt of a synthetic glucocorticoid receptor agonist with immunosuppressive and anti-inflammatory effects. Methylprednisolone sodium succinate is converted into active prednisolone in the body, which activates glucocorticoid receptor mediated gene expression. This includes inducing synthesis of anti-inflammatory protein IkappaB-alpha and inhibiting synthesis of nuclear factor kappaB (NF-kappaB). As a result, proinflammatory cytokine production such as IL-1, IL-2 and IL-6 is down-regulated and cytotoxic T-lymphocyte activation is inhibited. Therefore, an overall reduction in chronic inflammation and autoimmune reactions may be achieved.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68AE1FEE-6037-3A56-E053-F662850AAD03","latestVersionIndicator":"Yes","beginDate":"2018-03-30","endDate":null,"createdBy":"TSESU","dateCreated":"2018-03-30","modifiedBy":"ONEDATA","dateModified":"2018-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7EE3E4A7-CEB0-41D1-E053-F662850AD488","beginDate":"2019-01-07","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-01-07","modifiedBy":"ONEDATA","dateModified":"2019-01-07","deletedIndicator":"No"},{"value":"Radiation","valueDescription":"Radiation Therapy","ValueMeaning":{"publicId":"2567129","version":"1","preferredName":"Radiation Therapy","longName":"2567129","preferredDefinition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Radiation Therapy","conceptCode":"C15313","definition":"Treatment of a disease by means of exposure of the target or the whole body to radiation. Radiation therapy is often used as part of curative therapy and occasionally as a component of palliative treatment for cancer. Other uses include total body irradiation prior to transplantation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D346-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-10-21","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-10-21","modifiedBy":"KUMMEROA","dateModified":"2023-07-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BC02EE6-36A4-7086-E053-F662850A1D9F","beginDate":"2018-11-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"},{"value":"Thiotepa","valueDescription":"Thiotepa","ValueMeaning":{"publicId":"5810420","version":"1","preferredName":"Thiotepa","longName":"Thiopeta","preferredDefinition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","context":"NHLBI","contextVersion":"1","Concepts":[{"longName":"Thiotepa","conceptCode":"C875","definition":"A polyfunctional, organophosphorus alkylating agent and a stable derivative of N,N',N''-triethylenephosphoramide (TEPA), with antineoplastic activity. Upon administration, thiotepa is converted into highly reactive ethylenimine groups, which covalently bind to nucleophilic groups in DNA and demonstrate a preference for the N7 position of guanine bases. This induces crosslinking of alkylated guanine bases in double-stranded DNA, interferes with both DNA replication and cell division, and results in both the induction of apoptosis and the inhibition of cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F02410F-4E09-4DC7-E053-F662850A8F88","latestVersionIndicator":"Yes","beginDate":"2017-05-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-05-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"7BC02EE6-36AE-7086-E053-F662850A1D9F","beginDate":"2018-11-28","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2018-11-28","modifiedBy":"ONEDATA","dateModified":"2018-11-28","deletedIndicator":"No"},{"value":"Risedronate","valueDescription":"Risedronate Sodium","ValueMeaning":{"publicId":"5709611","version":"1","preferredName":"Risedronate Sodium","longName":"5709611","preferredDefinition":"The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Risedronate Sodium","conceptCode":"C1528","definition":"The sodium salt of risedronic acid, a synthetic pyridinyl bisphosphonate. Risedronic acid binds to hydroxyapatite crystals in bone and inhibits osteoclast-dependent bone resorption.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AA0A7DB-1CE4-7C8E-E053-F662850A3136","latestVersionIndicator":"Yes","beginDate":"2017-03-13","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2017-03-13","modifiedBy":"ZHANGWE","dateModified":"2021-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6CFFD6-3B79-6CA0-E053-F662850A8C78","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Everolimus","valueDescription":"Everolimus","ValueMeaning":{"publicId":"3379525","version":"1","preferredName":"Everolimus","longName":"3379525","preferredDefinition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Everolimus","conceptCode":"C48387","definition":"A derivative of the natural macrocyclic lactone sirolimus with immunosuppressant and anti-angiogenic properties. In cells, everolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian Target of Rapamycin (mTOR), a key regulatory kinase. Inhibition of mTOR activation results in the inhibition of T lymphocyte activation and proliferation associated with antigen and cytokine (IL-2, IL-4, and IL-15) stimulation and the inhibition of antibody production. (NCI05)","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B92BDDE2-3294-C61C-E040-BB89AD4317D7","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"COOPERM","dateModified":"2019-11-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6CBDA5-61B3-0BC1-E053-F662850A520D","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Axitinib","valueDescription":"Axitinib","ValueMeaning":{"publicId":"3107592","version":"1","preferredName":"Axitinib","longName":"3107592","preferredDefinition":"An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Axitinib","conceptCode":"C38718","definition":"An orally bioavailable tyrosine kinase inhibitor. Axitinib inhibits the proangiogenic cytokines vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGF), thereby exerting an anti-angiogenic effect.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8873406C-115B-C1CB-E040-BB89AD434472","latestVersionIndicator":"Yes","beginDate":"2010-06-07","endDate":null,"createdBy":"SHIDED","dateCreated":"2010-06-07","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6CBDA5-61BD-0BC1-E053-F662850A520D","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Avelumab + axitinib","valueDescription":"Avelumab And Axitinib Regimen","ValueMeaning":{"publicId":"6824782","version":"1","preferredName":"Avelumab And Axitinib Regimen","longName":"6824782","preferredDefinition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A chemotherapy regimen consisting of axitinib that may be used in the treatment of follicular, papillary and Hurthle cell thyroid carcinomas, and kidney cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Avelumab","conceptCode":"C116870","definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Axitinib Regimen","conceptCode":"C159994","definition":"A regimen consisting of axitinib that may be used in the treatment of follicular, papillary and Hurthle cell thyroid carcinomas, and kidney cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6CBDA5-61CB-0BC1-E053-F662850A520D","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6CBDA5-61E4-0BC1-E053-F662850A520D","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Pembrolizumab + axitinib","valueDescription":"Axitinib/Pembrolizumab Regimen","ValueMeaning":{"publicId":"6813211","version":"1","preferredName":"Axitinib/Pembrolizumab Regimen","longName":"6813211","preferredDefinition":"A regimen consisting of axitinib and pembrolizumab that can be used for the treatment of advanced renal cell carcinoma (RCC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Axitinib/Pembrolizumab Regimen","conceptCode":"C162220","definition":"A regimen consisting of axitinib and pembrolizumab that can be used for the treatment of renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8CCBCF1B-3EC6-3BEC-E053-F662850A5044","latestVersionIndicator":"Yes","beginDate":"2019-07-03","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-07-03","modifiedBy":"ONEDATA","dateModified":"2019-07-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6CBDA5-61F8-0BC1-E053-F662850A520D","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Pembrolizumab","valueDescription":"Pembrolizumab","ValueMeaning":{"publicId":"5076693","version":"1","preferredName":"Pembrolizumab","longName":"5076693v1.00","preferredDefinition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pembrolizumab","conceptCode":"C106432","definition":"A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EB81-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6CBDA5-6202-0BC1-E053-F662850A520D","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Nivolumab + ipilimumab","valueDescription":"Ipilimumab and Nivolumab Regimen","ValueMeaning":{"publicId":"6409150","version":"1","preferredName":"Ipilimumab and Nivolumab Regimen","longName":"6409150","preferredDefinition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of kidney cancer and melanoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab/Nivolumab Regimen","conceptCode":"C154272","definition":"A regimen consisting of ipilimumab and nivolumab that can be used for the treatment of bone cancer, kidney cancer, colorectal cancer, melanoma, non-small cell lung cancer (NSCLC), and malignant pleural/peritoneal mesothelioma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7409E9E8-661C-4EFE-E053-F662850A32CC","latestVersionIndicator":"Yes","beginDate":"2018-08-22","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-08-22","modifiedBy":"SOKKERL","dateModified":"2019-02-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6CBDA5-6216-0BC1-E053-F662850A520D","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Nivolumab","valueDescription":"Nivolumab","ValueMeaning":{"publicId":"5076694","version":"1","preferredName":"Nivolumab","longName":"5076694","preferredDefinition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nivolumab","conceptCode":"C68814","definition":"A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, nivolumab binds to and blocks the activation of PD-1, an immunoglobulin superfamily (IgSF) transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), which is overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen-presenting cells (APCs). This results in the activation of T-cells and cell-mediated immune responses against tumor cells. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2653AD7D-EBB8-5B33-E050-BB89AD437FF5","latestVersionIndicator":"Yes","beginDate":"2015-12-07","endDate":null,"createdBy":"ROSSD","dateCreated":"2015-12-07","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6CBDA5-6220-0BC1-E053-F662850A520D","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Cabozantinib","valueDescription":"Cabozantinib","ValueMeaning":{"publicId":"6824783","version":"1","preferredName":"Cabozantinib","longName":"6824783","preferredDefinition":"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabozantinib","conceptCode":"C52200","definition":"An orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E6CBDA5-622A-0BC1-E053-F662850A520D","latestVersionIndicator":"Yes","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"CLOHNES","dateModified":"2022-11-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E6CBDA5-6243-0BC1-E053-F662850A520D","beginDate":"2019-07-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-07-24","modifiedBy":"ONEDATA","dateModified":"2019-07-24","deletedIndicator":"No"},{"value":"Epigenetic therapy (for example, decitabine or azacitidine)","valueDescription":"Epigenetic therapy (for example, decitabine or azacitidine)","ValueMeaning":{"publicId":"6829536","version":"1","preferredName":"Epigenetic therapy (for example, decitabine or azacitidine)","longName":"6829536","preferredDefinition":"Epigenetic therapy (for example, decitabine or azacitidine)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6D85-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6D9E-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"Capizzi Dose Methotrexate (i.e. C-MTX)","valueDescription":"Capizzi Dose Methotrexate (i.e. C-MTX)","ValueMeaning":{"publicId":"6829537","version":"1","preferredName":"Capizzi Dose Methotrexate (i.e. C-MTX)","longName":"6829537","preferredDefinition":"Capizzi Dose Methotrexate (i.e. C-MTX)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6DA8-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"KUMMEROA","dateModified":"2023-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6DC1-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"High Dose Methotrexate (i.e. HDMTX)","valueDescription":"High Dose Methotrexate (i.e. HDMTX)","ValueMeaning":{"publicId":"6829538","version":"1","preferredName":"High Dose Methotrexate (i.e. HDMTX)","longName":"6829538","preferredDefinition":"High Dose Methotrexate (i.e. HDMTX)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6DCB-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"KUMMEROA","dateModified":"2023-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6DE4-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"High Dose Cytarabine +Asparaginase [\"HDAc-Asp,\" \"Capizzi II\"])","valueDescription":"High Dose Cytarabine +Asparaginase [\"HDAc-Asp,\" \"Capizzi II\"])","ValueMeaning":{"publicId":"6829539","version":"1","preferredName":"High Dose Cytarabine +Asparaginase [\"HDAc-Asp,\" \"Capizzi II\"])","longName":"6829539","preferredDefinition":"High Dose Cytarabine +Asparaginase [\"HDAc-Asp,\" \"Capizzi II\"])","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6DEE-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6E07-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"High dose Cytarabine >1gm/m2  (i.e. HDAc)","valueDescription":"High dose Cytarabine >1gm/m2  (i.e. HDAc)","ValueMeaning":{"publicId":"6829540","version":"1","preferredName":"High dose Cytarabine >1gm/m2  (i.e. HDAc)","longName":"6829540","preferredDefinition":"High dose Cytarabine >1gm/m2  (i.e. HDAc)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6E11-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6E2A-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"Fludarabine-High Dose Cytarabine  Filgrastim (i.e. FLAG, FLA)","valueDescription":"Fludarabine-High Dose Cytarabine  Filgrastim (i.e. FLAG, FLA)","ValueMeaning":{"publicId":"6829541","version":"1","preferredName":"Fludarabine-High Dose Cytarabine  Filgrastim (i.e. FLAG, FLA)","longName":"6829541","preferredDefinition":"Fludarabine-High Dose Cytarabine  Filgrastim (i.e. FLAG, FLA)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6E34-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6E4D-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"High Dose Cytarabine-Etoposide (i.e. AE)","valueDescription":"High Dose Cytarabine-Etoposide (i.e. AE)","ValueMeaning":{"publicId":"6829542","version":"1","preferredName":"High Dose Cytarabine-Etoposide (i.e. AE)","longName":"6829542","preferredDefinition":"High Dose Cytarabine-Etoposide (i.e. AE)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6E57-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6E70-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"Mitoxantrone+High Dose Cytarabine (i.e. MA, Mitox-AraC)","valueDescription":"Mitoxantrone+High Dose Cytarabine (i.e. MA, Mitox-AraC)","ValueMeaning":{"publicId":"6829543","version":"1","preferredName":"Mitoxantrone+High Dose Cytarabine (i.e. MA, Mitox-AraC)","longName":"6829543","preferredDefinition":"Mitoxantrone+High Dose Cytarabine (i.e. MA, Mitox-AraC)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6E7A-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6E93-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"ALL Delayed Intensification","valueDescription":"ALL Delayed Intensification","ValueMeaning":{"publicId":"6829544","version":"1","preferredName":"ALL Delayed Intensification","longName":"6829544","preferredDefinition":"ALL Delayed Intensification","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6E9D-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6EB6-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"Fludarabine-Cytarabine-Idarubicin  Filgrastim (i.e. FLAG-IDA, FLA-IDA)","valueDescription":"Fludarabine-Cytarabine-Idarubicin  Filgrastim (i.e. FLAG-IDA, FLA-IDA)","ValueMeaning":{"publicId":"6829545","version":"1","preferredName":"Fludarabine-Cytarabine-Idarubicin  Filgrastim (i.e. FLAG-IDA, FLA-IDA)","longName":"6829545","preferredDefinition":"Fludarabine-Cytarabine-Idarubicin  Filgrastim (i.e. FLAG-IDA, FLA-IDA)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6EC0-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6ED9-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"Cytarabine-Daunorubicin  Etoposide (i.e. ADE, DA)","valueDescription":"Cytarabine-Daunorubicin  Etoposide (i.e. ADE, DA)","ValueMeaning":{"publicId":"6829546","version":"1","preferredName":"Cytarabine-Daunorubicin  Etoposide (i.e. ADE, DA)","longName":"6829546","preferredDefinition":"Cytarabine-Daunorubicin  Etoposide (i.e. ADE, DA)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6EE3-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6EFC-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"Chimeric antigen receptor T cell therapy","valueDescription":"Chimeric antigen receptor T cell therapy","ValueMeaning":{"publicId":"6829535","version":"1","preferredName":"Chimeric antigen receptor T cell therapy","longName":"6829535","preferredDefinition":"Chimeric antigen receptor T cell therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8E85D0A6-6D62-7270-E053-F662850AC7AF","latestVersionIndicator":"Yes","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8E85D0A6-6D7B-7270-E053-F662850AC7AF","beginDate":"2019-07-25","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-25","modifiedBy":"ONEDATA","dateModified":"2019-07-25","deletedIndicator":"No"},{"value":"Acetaminophen","valueDescription":"Acetaminophen","ValueMeaning":{"publicId":"2575982","version":"1","preferredName":"Acetaminophen","longName":"2575982v1.00","preferredDefinition":"A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acetaminophen","conceptCode":"C198","definition":"A p-aminophenol derivative with analgesic and antipyretic activities. Although the exact mechanism through which acetaminophen exert its effects has yet to be fully determined, acetaminophen may inhibit the nitric oxide (NO) pathway mediated by a variety of neurotransmitter receptors including N-methyl-D-aspartate (NMDA) and substance P, resulting in elevation of the pain threshold. The antipyretic activity may result from inhibition of prostaglandin synthesis and release in the central nervous system (CNS) and prostaglandin-mediated effects on the heat-regulating center in the anterior hypothalamus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-24","modifiedBy":"MMADDINENI","dateModified":"2023-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED3BC62-4DE9-0C4A-E053-F662850AD15A","beginDate":"2019-07-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Famotidine","valueDescription":"Famotidine","ValueMeaning":{"publicId":"2576843","version":"1","preferredName":"Famotidine","longName":"2576843v1.00","preferredDefinition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Famotidine","conceptCode":"C29045","definition":"A propanimidamide and histamine H2-receptor antagonist with antacid activity. As a competitive inhibitor of histamine H2-receptors located on the basolateral membrane of the parietal cell, famotidine reduces basal and nocturnal gastric acid secretion, resulting in a reduction in gastric volume, acidity, and amount of gastric acid released in response to various stimuli.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F938-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-08","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-11-08","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8ED3BC62-4DF3-0C4A-E053-F662850AD15A","beginDate":"2019-07-29","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-07-29","modifiedBy":"ONEDATA","dateModified":"2019-07-29","deletedIndicator":"No"},{"value":"Levetiracetam","valueDescription":"Levetiracetam","ValueMeaning":{"publicId":"2578221","version":"1","preferredName":"Levetiracetam","longName":"2578221","preferredDefinition":"A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Levetiracetam","conceptCode":"C47581","definition":"A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FE9A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-03-14","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-03-14","modifiedBy":"ONEDATA","dateModified":"2006-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B293C99-B3BC-5F97-E053-F662850A6F5A","beginDate":"2020-01-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Clonazepam","valueDescription":"Clonazepam","ValueMeaning":{"publicId":"2577827","version":"1","preferredName":"Clonazepam","longName":"2577827","preferredDefinition":"A synthetic benzodiazepine derivative used for myotonic or atonic seizures, absence seizures, and photosensitive epilepsy, anticonvulsant Clonazepam appears to enhance gamma-aminobutyric acid receptor responses, although its mechanism of action is not clearly understood. It is seldom effective in generalized tonic-clonic or partial seizures. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clonazepam","conceptCode":"C28935","definition":"A synthetic benzodiazepine derivative used for myotonic or atonic seizures, absence seizures, and photosensitive epilepsy, anticonvulsant Clonazepam appears to enhance gamma-aminobutyric acid receptor responses, although its mechanism of action is not clearly understood. It is seldom effective in generalized tonic-clonic or partial seizures. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD10-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-08-29","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-08-29","modifiedBy":"REEVESD","dateModified":"2006-02-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9B293C99-B3C6-5F97-E053-F662850A6F5A","beginDate":"2020-01-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-01-02","modifiedBy":"ONEDATA","dateModified":"2020-01-02","deletedIndicator":"No"},{"value":"Tremelimumab","valueDescription":"Tremelimumab","ValueMeaning":{"publicId":"3185137","version":"1","preferredName":"Tremelimumab","longName":"3185137","preferredDefinition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tremelimumab","conceptCode":"C49085","definition":"A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A317-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9340E89E-6F71-7EA2-E053-F662850A2CEE","beginDate":"2019-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-24","modifiedBy":"ONEDATA","dateModified":"2019-09-24","deletedIndicator":"No"},{"value":"Ipilimumab","valueDescription":"Ipilimumab","ValueMeaning":{"publicId":"3185135","version":"1","preferredName":"Ipilimumab","longName":"3185135","preferredDefinition":"A monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen-4 (CTLA4), an antigen that is expressed on activated T-cells and exhibits affinity for B7 co-stimulatory molecules. By binding CTLA4, ipilimumab enhances T-cell activation and blocks B7-1 and B7-2 T-cell co-stimulatory pathways.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ipilimumab","conceptCode":"C2654","definition":"A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9A4E41E5-A2F1-57BF-E040-BB89AD4327A8","latestVersionIndicator":"Yes","beginDate":"2011-01-20","endDate":null,"createdBy":"ALAIS","dateCreated":"2011-01-20","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9340E89E-6F7B-7EA2-E053-F662850A2CEE","beginDate":"2019-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-24","modifiedBy":"ONEDATA","dateModified":"2019-09-24","deletedIndicator":"No"},{"value":"Durvalumab","valueDescription":"Durvalumab","ValueMeaning":{"publicId":"5755432","version":"1","preferredName":"Durvalumab","longName":"5755432","preferredDefinition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Durvalumab","conceptCode":"C103194","definition":"A monoclonal antibody directed against B7H1 (B7 homolog 1; programmed cell death ligand 1) with potential immunostimulating activity. Upon intravenous administration, durvalumab binds to the cell surface antigen B7H1, thereby blocking B7H1 signaling. This may activate the immune system to exert a cytotoxic T-lymphocyte (CTL) response against B7H1-expressing tumor cells. B7H1, a member of the B7 protein superfamily and a negative regulator of cytokine synthesis, is overexpressed on certain tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4CFD0718-5F32-7D12-E053-F662850AD37E","latestVersionIndicator":"Yes","beginDate":"2017-04-12","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-04-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9340E89E-6F85-7EA2-E053-F662850A2CEE","beginDate":"2019-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-24","modifiedBy":"ONEDATA","dateModified":"2019-09-24","deletedIndicator":"No"},{"value":"Cemiplimab","valueDescription":"Cemiplimab","ValueMeaning":{"publicId":"6687982","version":"1","preferredName":"Cemiplimab","longName":"6687982","preferredDefinition":"A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cemiplimab","conceptCode":"C121540","definition":"A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-cells. PD-1, a transmembrane protein in the immunoglobulin superfamily expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligand; it plays an important role in tumor evasion from host immunity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"86084999-63D2-7CF3-E053-F662850ABF0E","latestVersionIndicator":"Yes","beginDate":"2019-04-08","endDate":null,"createdBy":"COOPERM","dateCreated":"2019-04-08","modifiedBy":"ONEDATA","dateModified":"2019-04-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9340E89E-6F8F-7EA2-E053-F662850A2CEE","beginDate":"2019-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-24","modifiedBy":"ONEDATA","dateModified":"2019-09-24","deletedIndicator":"No"},{"value":"Avelumab","valueDescription":"Avelumab","ValueMeaning":{"publicId":"5799363","version":"1","preferredName":"Avelumab","longName":"5799363","preferredDefinition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Avelumab","conceptCode":"C116870","definition":"A human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human immunosuppressive ligand programmed death-ligand 1 (PD-L1) protein, with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, avelumab binds to PD-L1 and prevents the interaction of PD-L1 with its receptor programmed cell death protein 1 (PD-1). This inhibits the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of cytotoxic T-lymphocytes (CTLs) targeted to PD-L1-overexpressing tumor cells. In addition, avelumab induces an antibody-dependent cellular cytotoxic (ADCC) response against PD-L1-expressing tumor cells. PD-1, a cell surface receptor belonging to the immunoglobulin superfamily expressed on T-cells, negatively regulates T-cell activation and effector function when activated by its ligand, and plays an important role in tumor evasion from host immunity. PD-L1, a transmembrane protein, is overexpressed on a variety of tumor cell types and is associated with poor prognosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4E757D46-6B00-5282-E053-F662850AE968","latestVersionIndicator":"Yes","beginDate":"2017-05-01","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2017-05-01","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9340E89E-6F99-7EA2-E053-F662850A2CEE","beginDate":"2019-09-24","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-24","modifiedBy":"ONEDATA","dateModified":"2019-09-24","deletedIndicator":"No"},{"value":"Nab-paclitaxel","valueDescription":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation","ValueMeaning":{"publicId":"5567089","version":"1","preferredName":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation","longName":"5567089","preferredDefinition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nab-paclitaxel","conceptCode":"C2688","definition":"A Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. This formulation solubilizes paclitaxel without the use of the solvent Cremophor, thereby permitting the administration of larger doses of paclitaxel while avoiding the toxic effects associated with Cremophor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"40CFD039-BC75-556D-E053-F662850AED1E","latestVersionIndicator":"Yes","beginDate":"2016-11-08","endDate":null,"createdBy":"PATELV","dateCreated":"2016-11-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"93766C0F-84FD-5CDC-E053-F662850A7A93","beginDate":"2019-09-26","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-09-26","modifiedBy":"ONEDATA","dateModified":"2019-09-26","deletedIndicator":"No"},{"value":"Obeticholic Acid","valueDescription":"Obeticholic Acid","ValueMeaning":{"publicId":"7515884","version":"1","preferredName":"Obeticholic Acid","longName":"7515884v1.00","preferredDefinition":"An orally bioavailable semi-synthetic bile acid derivative and an agonist of the nuclear bile acid receptor farnesoid X receptor (FXR) that may be used to lower hepatic exposure to bile acids. Upon oral administration, obeticholic acid targets and binds to FXR expressed in the liver and intestine, activating FXR-mediated bile acid, inflammatory, fibrotic, and metabolic pathways. This suppresses the production of bile acid in the hepatocytes and increases bile acid transport out of the hepatocytes, thereby reducing hepatic exposure to bile acids. FXR plays an important role in bile acid homeostasis and is involved in hepatic and intestinal inflammation and liver fibrosis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Obeticholic Acid","conceptCode":"C80837","definition":"An orally bioavailable semi-synthetic bile acid derivative and an agonist of the nuclear bile acid receptor farnesoid X receptor (FXR) that may be used to lower hepatic exposure to bile acids. Upon oral administration, obeticholic acid targets and binds to FXR expressed in the liver and intestine, activating FXR-mediated bile acid, inflammatory, fibrotic, and metabolic pathways. This suppresses the production of bile acid in the hepatocytes and increases bile acid transport out of the hepatocytes, thereby reducing hepatic exposure to bile acids. FXR plays an important role in bile acid homeostasis and is involved in hepatic and intestinal inflammation and liver fibrosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B4DF60D8-512E-12FF-E053-4EBD850A9790","latestVersionIndicator":"Yes","beginDate":"2020-11-24","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2020-11-24","modifiedBy":"KUMMEROA","dateModified":"2023-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4DF60D8-5149-12FF-E053-4EBD850A9790","beginDate":"2020-11-24","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2020-11-24","modifiedBy":"ONEDATA","dateModified":"2020-11-24","deletedIndicator":"No"},{"value":"Placebo","valueDescription":"Placebo","ValueMeaning":{"publicId":"3228305","version":"1","preferredName":"Placebo","longName":"3228305","preferredDefinition":"An inactive substance, treatment or procedure that is intended to mimic as closely as possible a therapy in a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A15C7F84-4B5D-4B63-E040-BB89AD432192","latestVersionIndicator":"Yes","beginDate":"2011-04-20","endDate":null,"createdBy":"MAESKEB","dateCreated":"2011-04-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B4DF60D8-5153-12FF-E053-4EBD850A9790","beginDate":"2020-11-24","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2020-11-24","modifiedBy":"ONEDATA","dateModified":"2020-11-24","deletedIndicator":"No"},{"value":"Calaspargase (Asparlas)","valueDescription":"Calaspargase Pegol-mknl","ValueMeaning":{"publicId":"7533532","version":"1","preferredName":"Calaspargase Pegol-mknl","longName":"7533532","preferredDefinition":"A drug used to treat acute lymphoblastic leukemia (ALL). It is a form of the anticancer drug PEG-asparaginase that stays in the body longer. EZN-2285 is an enzyme that breaks down the amino acid asparagine and may block the growth of tumor cells that need asparagine to grow. It is a type of protein synthesis inhibitor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Calaspargase Pegol","conceptCode":"C78198","definition":"An intravenous formulation containing E.coli-derived L-asparaginase II conjugated with succinimidyl carbonate monomethoxypolyethylene glycol (SC-PEG), with potential antineoplastic activity. Upon administration of calaspargase pegol, L-asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting cells of asparagine; asparagine depletion blocks protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle and ultimately induces tumor cell death. Asparagine is critical to protein synthesis in acute lymphoblastic leukemia (ALL) cells which, unlike normal cells, cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Pegylation decreases enzyme antigenicity and increases its half life. SC is used as a PEG linker to facilitate attachment to asparaginase and enhances the stability of the formulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6866E93-FFD6-5317-E053-4EBD850AC14A","latestVersionIndicator":"Yes","beginDate":"2020-12-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-15","modifiedBy":"KUMMEROA","dateModified":"2023-06-28","changeDescription":null,"administrativeNotes":"2023.6.28 Alt VM added per ticket request CADSR0002550. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6866E93-FFEF-5317-E053-4EBD850AC14A","beginDate":"2020-12-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"Pegaspargase (Oncaspar)","valueDescription":"Pegaspargase","ValueMeaning":{"publicId":"3379428","version":"1","preferredName":"Pegaspargase","longName":"3379428","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B9293EA5-2066-3D6D-E040-BB89AD4348A8","latestVersionIndicator":"Yes","beginDate":"2012-02-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-17","modifiedBy":"KUMMEROA","dateModified":"2022-11-17","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B6866E94-0003-5317-E053-4EBD850AC14A","beginDate":"2020-12-15","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2020-12-15","modifiedBy":"ONEDATA","dateModified":"2020-12-15","deletedIndicator":"No"},{"value":"ACT","valueDescription":"AC Regimen And Paclitaxel","ValueMeaning":{"publicId":"7651566","version":"1","preferredName":"AC Regimen And Paclitaxel","longName":"7651566","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin, used in the neoadjuvant and adjuvant treatment for breast cancer; also used as a treatment for recurrent and metastatic breast cancer.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AC Regimen","conceptCode":"C63415","definition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin, used in the neoadjuvant and adjuvant treatment for breast cancer; also used as a treatment for recurrent and metastatic breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Paclitaxel","conceptCode":"C1411","definition":"A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity.  Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division.  This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1845C20-AE34-7528-E053-4EBD850AEE78","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1845C20-AE4D-7528-E053-4EBD850AEE78","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","deletedIndicator":"No"},{"value":"CMF","valueDescription":"CMF Regimen","ValueMeaning":{"publicId":"4593995","version":"1","preferredName":"CMF Regimen","longName":"4593995","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide, methotrexate, and fluorouracil, which may be used in the adjuvant setting for the treatment of nonmetastatic breast cancer or alone for the treatment of metastatic breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CMF Regimen","conceptCode":"C9874","definition":"A chemotherapy regimen consisting of cyclophosphamide, methotrexate and fluorouracil, used as a neoadjuvant or adjuvant treatment for breast cancer; also used for the treatment of recurrent and metastatic breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"07DA3024-47B1-8126-E050-BB89AD43688C","latestVersionIndicator":"Yes","beginDate":"2014-11-14","endDate":null,"createdBy":"RODGERSC","dateCreated":"2014-11-14","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1845C20-AE25-7528-E053-4EBD850AEE78","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","deletedIndicator":"No"},{"value":"Metformin","valueDescription":"Metformin","ValueMeaning":{"publicId":"3189685","version":"1","preferredName":"Metformin","longName":"3189685v1.00","preferredDefinition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metformin","conceptCode":"C61612","definition":"An agent belonging to the biguanide class of antidiabetics with antihyperglycemic activity. Metformin is associated with a very low incidence of lactic acidosis. This agent helps reduce LDL cholesterol and triglyceride levels, and is not associated with weight gain, and prevents the cardiovascular complications of diabetes. Metformin is not metabolized and is excreted unchanged by the kidneys.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9BB1D0F5-1252-2360-E040-BB89AD4328D8","latestVersionIndicator":"Yes","beginDate":"2011-02-07","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-02-07","modifiedBy":"MMADDINENI","dateModified":"2022-10-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BC305F7C-B733-2CDD-E053-4EBD850A5FBD","beginDate":"2021-02-25","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-02-25","modifiedBy":"ONEDATA","dateModified":"2021-02-25","deletedIndicator":"No"},{"value":"FAC","valueDescription":"FAC Regimen","ValueMeaning":{"publicId":"7651572","version":"1","preferredName":"FAC Regimen","longName":"7651572","preferredDefinition":"A chemotherapy regimen consisting of fluorouracil, doxorubicin and intravenous cyclophosphamide, used as a treatment for recurrent and metastatic breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FAC Regimen","conceptCode":"C138099","definition":"A chemotherapy regimen consisting of fluorouracil, doxorubicin and intravenous cyclophosphamide, used as a treatment for recurrent and metastatic breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C18493B6-19C1-03B4-E053-4EBD850AA483","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C18493B6-19DA-03B4-E053-4EBD850AA483","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","deletedIndicator":"No"},{"value":"AC","valueDescription":"AC Regimen","ValueMeaning":{"publicId":"7651573","version":"1","preferredName":"AC Regimen","longName":"7651573","preferredDefinition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin, used in the neoadjuvant and adjuvant treatment for breast cancer; also used as a treatment for recurrent and metastatic breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AC Regimen","conceptCode":"C63415","definition":"A chemotherapy regimen consisting of cyclophosphamide and doxorubicin, used in the neoadjuvant and adjuvant treatment for breast cancer; also used as a treatment for recurrent and metastatic breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C18493B6-19E6-03B4-E053-4EBD850AA483","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C18493B6-19FF-03B4-E053-4EBD850AA483","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","deletedIndicator":"No"},{"value":"Sacituzumab govitecan","valueDescription":"Sacituzumab Govitecan","ValueMeaning":{"publicId":"7651581","version":"1","preferredName":"Sacituzumab govitecan","longName":"7651581v1.00","preferredDefinition":"An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sacituzumab Govitecan","conceptCode":"C102783","definition":"An antibody drug conjugate containing the humanized monoclonal antibody, hRS7, against tumor-associated calcium signal transducer 2 (TACSTD2 or TROP2) and linked to the active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), with potential antineoplastic activity. The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomerase I-DNA covalent complexes, resulting in DNA breaks that inhibit DNA replication and trigger apoptosis. TROP2, also known as epithelial glycoprotein-1 (EGP-1), is a transmembrane calcium signal transducer that is overexpressed by a variety of human epithelial carcinomas; this antigen is involved in the regulation of cell-cell adhesion and its expression is associated with increased cancer growth, aggressiveness and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1823ADF-D239-476E-E053-4EBD850A6959","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"FINCHAMB","dateModified":"2024-01-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1823ADF-D254-476E-E053-4EBD850A6959","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","deletedIndicator":"No"},{"value":"Talazoparib","valueDescription":"Talazoparib","ValueMeaning":{"publicId":"6159964","version":"1","preferredName":"Talazoparib","longName":"6159964","preferredDefinition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Talazoparib","conceptCode":"C95733","definition":"An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential antineoplastic activity. Talazoparib selectively binds to PARP and prevents PARP-mediated DNA repair of single strand DNA breaks via the base-excision repair pathway. This enhances the accumulation of DNA strand breaks, promotes genomic instability and eventually leads to apoptosis. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins that signal and recruit other proteins to repair damaged DNA and is activated by single-strand DNA breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68D489E2-0031-7061-E053-F662850A5645","latestVersionIndicator":"Yes","beginDate":"2018-04-01","endDate":null,"createdBy":"TSESU","dateCreated":"2018-04-01","modifiedBy":"ONEDATA","dateModified":"2018-04-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1823ADF-D268-476E-E053-4EBD850A6959","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","deletedIndicator":"No"},{"value":"XMN","valueDescription":"Capecitabine Methotrexate And Vinorelbine Tartrate Chemotherapy","ValueMeaning":{"publicId":"7651582","version":"1","preferredName":"Capecitabine Methotrexate And Vinorelbine Tartrate Chemotherapy","longName":"7651582","preferredDefinition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04): An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04): The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Capecitabine","conceptCode":"C1794","definition":"A fluoropyrimidine carbamate belonging to the class of antineoplastic agents called antimetabolites.  As a prodrug, capecitabine is selectively activated by tumor cells to its cytotoxic moiety, 5-fluorouracil (5-FU); subsequently, 5-FU is metabolized to two active metabolites, 5-fluoro-2-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP) by both tumor cells and normal cells.  FdUMP inhibits DNA synthesis and cell division by reducing normal thymidine production, while FUTP inhibits RNA and protein synthesis by competing with uridine triphosphate for incorporation into the RNA strand. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Methotrexate","conceptCode":"C642","definition":"An antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Vinorelbine Tartrate","conceptCode":"C1395","definition":"The ditartrate salt of a semisynthetic vinca alkaloid derived from the leaves of the periwinkle plant (Vinca rosea) with antineoplastic properties.  Vinorelbine binds to tubulin, thereby inhibiting tubulin polymerization into microtubules and spindle formation and resulting in apoptosis of susceptible cancer cells. Inhibition of mitotic microtubules correlates with antitumor activity, whereas inhibition of axonal microtubules seems to correlate with vinorelbine's neurotoxicity. Compared to related vinca alkaloids, vinorelbine is more selective against mitotic than axonal microtubules in vitro, which may account for its decreased neurotoxicity.  This agent is also a radiation-sensitizing agent. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Chemotherapy","conceptCode":"C15632","definition":"The use of synthetic or naturally-occurring chemicals for the treatment of diseases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1823ADF-D278-476E-E053-4EBD850A6959","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1823ADF-D291-476E-E053-4EBD850A6959","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","deletedIndicator":"No"},{"value":"TCH","valueDescription":"TCH Regimen","ValueMeaning":{"publicId":"6005253","version":"1","preferredName":"TCH Regimen","longName":"6005253","preferredDefinition":"A chemotherapy regimen consisting of docetaxel, carboplatin and trastuzumab, used as a neoadjuvant or adjuvant treatment for HER-2/neu-positive breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TCH Regimen","conceptCode":"C63424","definition":"A regimen consisting of docetaxel, carboplatin and trastuzumab that can be used in the treatment of breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5BD3A3AE-5045-1705-E053-F662850A75D8","latestVersionIndicator":"Yes","beginDate":"2017-10-18","endDate":null,"createdBy":"MORENOC","dateCreated":"2017-10-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1823ADF-D29B-476E-E053-4EBD850A6959","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","deletedIndicator":"No"},{"value":"TAC","valueDescription":"TAC Regimen","ValueMeaning":{"publicId":"7651584","version":"1","preferredName":"TAC Regimen","longName":"7651584","preferredDefinition":"A chemotherapy regimen consisting of docetaxel, doxorubicin and cyclophosphamide, used as a neoadjuvant or adjuvant treatment for breast cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"TAC Regimen","conceptCode":"C63435","definition":"A regimen consisting of docetaxel, doxorubicin and cyclophosphamide that can be used in the treatment of breast cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C1823ADF-D2A8-476E-E053-4EBD850A6959","latestVersionIndicator":"Yes","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"C1823ADF-D2C1-476E-E053-4EBD850A6959","beginDate":"2021-05-04","endDate":null,"createdBy":"TITARENKOI","dateCreated":"2021-05-04","modifiedBy":"ONEDATA","dateModified":"2021-05-04","deletedIndicator":"No"},{"value":"Asparaginase Erwinia chrysanthemi","valueDescription":"Asparaginase Erwinia chrysanthemi","ValueMeaning":{"publicId":"7331406","version":"1","preferredName":"Asparaginase Erwinia chrysanthemi","longName":"7331406","preferredDefinition":"An enzyme isolated from the bacterium Erwinia chrysanthemi (E. carotovora). Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting leukemic cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  This agent also induces apoptosis in tumor cells. The Erwinia-derived product is often used for those patients who have experienced a hypersensitivity reaction to the E. Coli formulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Asparaginase Erwinia chrysanthemi","conceptCode":"C64260","definition":"A recombinant form of asparaginase derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration, asparaginase Erwinia chrysanthemi hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. Asparaginase Erwinia chrysanthemi can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A7D4A25B-38C5-566A-E053-4EBD850AA9EA","latestVersionIndicator":"Yes","beginDate":"2020-06-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2020-06-11","modifiedBy":"KUMMEROA","dateModified":"2023-06-28","changeDescription":null,"administrativeNotes":"2023.6.28 Alt VM added per ticket request CADSR0002550. ak 2022.12.1 Alt VM added for ticket CADSR0001748. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D2814BFF-3238-07D0-E053-4EBD850A8752","beginDate":"2021-12-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2021-12-06","modifiedBy":"ONEDATA","dateModified":"2021-12-06","deletedIndicator":"No"},{"value":"Pembrolizumab + Lenvatinib","valueDescription":"Pembrolizumab + Lenvatinib","ValueMeaning":{"publicId":"7997756","version":"1","preferredName":"Pembrolizumab + Lenvatinib","longName":"7997756v1.00","preferredDefinition":"A regimen consisting of lenvatinib and pembrolizumab that may be used for the treatment of cutaneous melanoma, hepatobiliary cancers, advanced endometrial carcinoma and advanced renal cell carcinoma (RCC).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lenvatinib/Pembrolizumab Regimen","conceptCode":"C180910","definition":"A regimen consisting of lenvatinib and pembrolizumab that may be used for the treatment of cutaneous melanoma, hepatobiliary cancers, advanced endometrial carcinoma and advanced renal cell carcinoma (RCC).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D4DABDBB-D6D2-597E-E053-4EBD850A99CC","latestVersionIndicator":"Yes","beginDate":"2022-01-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-01-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D4DABDBB-D6EB-597E-E053-4EBD850A99CC","beginDate":"2022-01-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-01-05","modifiedBy":"ONEDATA","dateModified":"2022-01-05","deletedIndicator":"No"},{"value":"Nivolumab + Cabozantinib","valueDescription":"Nivolumab + Cabozantinib","ValueMeaning":{"publicId":"7997757","version":"1","preferredName":"Nivolumab + Cabozantinib","longName":"7997757v1.00","preferredDefinition":"A regimen consisting of cabozantinib and nivolumab that can be used in the treatment of kidney cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cabozantinib/Nivolumab Regimen","conceptCode":"C192146","definition":"A regimen consisting of cabozantinib and nivolumab that can be used in the treatment of kidney cancer.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D4DABDBB-D6F5-597E-E053-4EBD850A99CC","latestVersionIndicator":"Yes","beginDate":"2022-01-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-01-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"D4DABDBB-D70E-597E-E053-4EBD850A99CC","beginDate":"2022-01-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2022-01-05","modifiedBy":"ONEDATA","dateModified":"2022-01-05","deletedIndicator":"No"},{"value":"Olaparib","valueDescription":"Olaparib","ValueMeaning":{"publicId":"3377423","version":"1","preferredName":"Olaparib","longName":"3377423","preferredDefinition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Olaparib","conceptCode":"C71721","definition":"A small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) with potential chemosensitizing, radiosensitizing, and antineoplastic activities. Olaparib selectively binds to and inhibits PARP, inhibiting PARP-mediated repair of single strand DNA breaks; PARP inhibition may enhance the cytotoxicity of DNA-damaging agents and may reverse tumor cell chemoresistance and radioresistance. PARP catalyzes post-translational ADP-ribosylation of nuclear proteins and can be activated by single-stranded DNA breaks.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8DFB740-1C92-299D-E040-BB89AD430A5E","latestVersionIndicator":"Yes","beginDate":"2012-02-13","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-13","modifiedBy":"COOPERM","dateModified":"2018-04-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DA3A8C24-6F64-4D91-E053-4EBD850A820C","beginDate":"2022-03-14","endDate":null,"createdBy":"ZHANGWE","dateCreated":"2022-03-14","modifiedBy":"ONEDATA","dateModified":"2022-03-14","deletedIndicator":"No"},{"value":"Metformin ER/Placebo","valueDescription":null,"ValueMeaning":{"publicId":"10931158","version":"1","preferredName":"Extended Release Metformin Hydrochloride Or Placebo","longName":"10931158v1.00","preferredDefinition":"An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin, with antihyperglycemic and potential prostate-cancer protective and antineoplastic activities. Upon oral administration, metformin targets and inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular adenosine monophosphate (AMP) to adenosine triphosphate (ATP) ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. This lowers blood glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. It also reduces cyclin D1. This inhibits cancer cell proliferation. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. Also, metformin reduces hyperinsulinemia which may contribute to an anti-tumor effect. Metformin may increase the prostate-specific antigen (PSA) doubling time and may lower serum PSA levels._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Extended Release Metformin Hydrochloride","conceptCode":"C173523","definition":"An extended-release (ER) tablet composed of the hydrochloride salt form of the biguanide metformin, with antihyperglycemic and potential prostate-cancer protective and antineoplastic activities. Upon oral administration, metformin targets and inhibits complex I (NADPH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain and increases the cellular adenosine monophosphate (AMP) to adenosine triphosphate (ATP) ratio leading to activation of AMP-activated protein kinase (AMPK). This modulates AMPK-mediated transcription of target genes, which prevents hepatic gluconeogenesis, decreases intestinal absorption of glucose, enhances insulin sensitivity and fatty acid oxidation, and increases glucose uptake and utilization in target tissues. This lowers blood glucose levels. Metformin may exert antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mammalian target of rapamycin (mTOR), which is up-regulated in many cancer tissues. It also reduces cyclin D1. This inhibits cancer cell proliferation. Furthermore, this agent also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression which is mediated through the suppression of transcription activator protein-1 (AP-1) activation. Also, metformin reduces hyperinsulinemia which may contribute to an anti-tumor effect. Metformin may increase the prostate-specific antigen (PSA) doubling time and may lower serum PSA levels.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5588E22-CD78-379A-E053-731AD00AB931","latestVersionIndicator":"Yes","beginDate":"2022-08-03","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-08-03","modifiedBy":"MMADDINENI","dateModified":"2022-08-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5588E22-CD79-379A-E053-731AD00AB931","beginDate":"2022-08-03","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-08-03","modifiedBy":"MMADDINENI","dateModified":"2022-08-03","deletedIndicator":"No"},{"value":"Ad5-CEA/Placebo","valueDescription":null,"ValueMeaning":{"publicId":"11167755","version":"1","preferredName":"Adenoviral Vector Ad5-CEA(6D) Vaccine Or Placebo","longName":"11167755v1.00","preferredDefinition":"A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoviral Vector Ad5-CEA(6D) Vaccine","conceptCode":"C91373","definition":"A replication-defective, E1- and E2b-deleted oncolytic adenoviral serotype 5 (Ad5) encoding an epitope of human carcinoembryonic antigen (CEA) with potential antineoplastic activity. Adenoviral vector Ad5-CEA(6D) vaccine expresses a highly immunogenic analogue of CEA [CAP1-(6D)]. Upon administration, this vaccine may induce both humoral and cellular immune responses against tumor cells expressing the CEA antigen, thereby resulting in the immune-mediated inhibition of tumor cell proliferation and tumor cell death. CEA, a tumor-associated antigen, is overexpressed in various tumor cell types. Deletion of early genes E1 and E2b in Ad5 potentially circumvent pre-existing anti-adenovirus immunity and is capable of inducing strong immune responses.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7B880F9-15F1-413F-E053-731AD00AE794","latestVersionIndicator":"Yes","beginDate":"2022-09-02","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-02","modifiedBy":"MMADDINENI","dateModified":"2022-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7B880F9-15F3-413F-E053-731AD00AE794","beginDate":"2022-09-02","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-02","modifiedBy":"MMADDINENI","dateModified":"2022-09-02","deletedIndicator":"No"},{"value":"N-803/Placebo","valueDescription":null,"ValueMeaning":{"publicId":"11167756","version":"1","preferredName":"Nogapendekin Alfa Or Placebo","longName":"11167756v1.00","preferredDefinition":"A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex N-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nogapendekin Alfa","conceptCode":"C107503","definition":"A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL-15Ra) Fc fusion protein (IL-15Ra-Fc) (IL-15N72D/IL-15Ra-Fc), with potential antineoplastic activity. Upon administration, superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex N-803 binds to the IL-2/IL-15 receptor beta-common gamma chain (IL-2Rbetagamma) receptor on natural killer (NK) and CD8+ T lymphocytes, which activates and increases the levels of NK cells and memory CD8+(CD44high) T-cells. The memory T-cells enhance the secretion of the cytokine interferon-gamma (IFN-g), which further potentiates the immune response against tumor cells. This may increase tumor cell killing and decrease tumor cell proliferation. IL-15 regulates CD8+ T and NK cell development, activation and proliferation. By coupling IL-15 to IL15Ra-Fc, this agent has a prolonged drug half-life and shows an increased ability to bind IL-2Rbetagamma, which enhances its immune stimulatory activity as compared to IL-15 alone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7B880F9-15F2-413F-E053-731AD00AE794","latestVersionIndicator":"Yes","beginDate":"2022-09-02","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-02","modifiedBy":"MMADDINENI","dateModified":"2022-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7B880F9-15F4-413F-E053-731AD00AE794","beginDate":"2022-09-02","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-02","modifiedBy":"MMADDINENI","dateModified":"2022-09-02","deletedIndicator":"No"},{"value":"Ad5-MUC1/Placebo","valueDescription":null,"ValueMeaning":{"publicId":"11262140","version":"1","preferredName":"Adenoviral MUC1 Vaccine ETBX-061 And Placebo","longName":"11262140v1.00","preferredDefinition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoviral MUC1 Vaccine ETBX-061","conceptCode":"C143035","definition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1 vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane protein, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9088559-090A-6C8A-E053-731AD00AFB8E","latestVersionIndicator":"Yes","beginDate":"2022-09-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-19","modifiedBy":"MMADDINENI","dateModified":"2022-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9088559-090C-6C8A-E053-731AD00AFB8E","beginDate":"2022-09-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-19","modifiedBy":"MMADDINENI","dateModified":"2022-09-19","deletedIndicator":"No"},{"value":"Ad5-brachyury/Placebo","valueDescription":null,"ValueMeaning":{"publicId":"11262141","version":"1","preferredName":"Adenoviral Brachyury Vaccine ETBX-051 And Placebo","longName":"11262141v1.00","preferredDefinition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis._An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence._An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adenoviral Brachyury Vaccine ETBX-051","conceptCode":"C143034","definition":"A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus (Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted, and the human transcription factor brachyury encoded, with potential immunostimulating and antineoplastic activities. Upon subcutaneous administration, the adenoviral brachyury vaccine ETBX-051 expresses the brachyury protein. The expressed brachyury may induce a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells expressing brachyury, thereby resulting in both immune-mediated inhibition of tumor cell proliferation and tumor cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus immune responses. Brachyury, a tumor-associated antigen (TAA) and member of the T-box family of transcription factors, is overexpressed in a variety of tumor types. It plays an important role in cancer progression and metastasis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E9088559-090B-6C8A-E053-731AD00AFB8E","latestVersionIndicator":"Yes","beginDate":"2022-09-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-19","modifiedBy":"MMADDINENI","dateModified":"2022-09-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E9088559-090D-6C8A-E053-731AD00AFB8E","beginDate":"2022-09-19","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2022-09-19","modifiedBy":"MMADDINENI","dateModified":"2022-09-19","deletedIndicator":"No"},{"value":"Recombinant Erwinia asparaginase JZP-458","valueDescription":null,"ValueMeaning":{"publicId":"12119549","version":"1","preferredName":"Recombinant Erwinia asparaginase JZP-458","longName":"12119549v1.00","preferredDefinition":"A recombinant form of asparaginase (Erwinia asparaginase; crisantaspase) derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration of recombinant Erwinia asparaginase JZP-458, the recombinant asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. JZP-458 can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Recombinant Erwinia asparaginase JZP-458","conceptCode":"C167120","definition":"A recombinant form of asparaginase (Erwinia asparaginase; crisantaspase) derived from the bacterium Erwinia chrysanthemi, genetically engineered to be produced in Pseudomonas fluorescens, with potential antineoplastic activity. Upon administration of recombinant Erwinia asparaginase JZP-458, the recombinant asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia. This depletes cancer cells of asparagine, which blocks protein synthesis and tumor cell proliferation. Asparagine is critical to protein synthesis in cancer cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. JZP-458 can be used as an alternative in patients who are hypersensitive to Escherichia (E.) coli-derived asparaginase products.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EECAA6D4-68E4-7A3A-E053-731AD00AB5DD","latestVersionIndicator":"Yes","beginDate":"2022-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-12-01","modifiedBy":"KUMMEROA","dateModified":"2023-06-28","changeDescription":null,"administrativeNotes":"2023.6.28 Alt VM added per ticket request CADSR0002550. ak 2022.12.1 Added Alt VM for ticket request CADSR0001748. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"EECAA6D4-68E5-7A3A-E053-731AD00AB5DD","beginDate":"2022-12-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2022-12-01","modifiedBy":"KUMMEROA","dateModified":"2022-12-01","deletedIndicator":"No"},{"value":"0.005% Calcipotriene plus 5% 5-FU","valueDescription":null,"ValueMeaning":{"publicId":"14216933","version":"1","preferredName":"0.005% Calcipotriene plus 5% 5-FU","longName":"14216933v1.00","preferredDefinition":"0.005% Calcipotriene plus 5% 5-FU","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"019075AC-7FCF-1C3A-E063-731AD00AD1E6","latestVersionIndicator":"Yes","beginDate":"2023-07-28","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2023-07-28","modifiedBy":"RAGUNATHANU","dateModified":"2023-07-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"019075AC-7FD0-1C3A-E063-731AD00AD1E6","beginDate":"2023-07-28","endDate":null,"createdBy":"RAGUNATHANU","dateCreated":"2023-07-28","modifiedBy":"RAGUNATHANU","dateModified":"2023-07-28","deletedIndicator":"No"},{"value":"BSSE/Placebo","valueDescription":null,"ValueMeaning":{"publicId":"14411456","version":"1","preferredName":"Broccoli Sprout/Broccoli Seed Extract Supplement Placebo","longName":"14411456v1.00","preferredDefinition":"A tablet-based nutritional supplement composed of a mixture of sprout and seed extracts of the cruciferous vegetable broccoli, with potential chemopreventive and antioxidant activities. Broccoli sprout/broccoli seed extract contains a high amount of both the glycosinolate glucoraphanin and the enzyme myrosinase, which catalyzes the production of glucoraphanin to sulforaphane. Upon administration of the broccoli sprout/broccoli seed extract, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs promote the transcription of antioxidant and detoxifying enzymes, particularly glutathione-S-transferase and NAD(P)H dehydrogenase [quinone] 1 (NAD(P)H:quinone oxidoreductase; NQO1), resulting in the detoxification of highly reactive carcinogens. This accelerates the elimination of carcinogens, may protect against cellular damage, and prevents cancer formation. AREs are cis-acting regulatory enhancer elements found in the 5' flanking region of many phase II detoxification enzymes._An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Broccoli Sprout/Broccoli Seed Extract Supplement","conceptCode":"C128293","definition":"A tablet-based nutritional supplement composed of a mixture of sprout and seed extracts of the cruciferous vegetable broccoli, with potential chemopreventive and antioxidant activities. Broccoli sprout/broccoli seed extract contains a high amount of both the glycosinolate glucoraphanin and the enzyme myrosinase, which catalyzes the production of glucoraphanin to sulforaphane. Upon administration of the broccoli sprout/broccoli seed extract, sulforaphane activates the transcription factor NF-E2-related factor 2 (Nrf2), a member of the basic leucine zipper family, which binds to and activates antioxidant-response elements (AREs). Subsequently, activated AREs promote the transcription of antioxidant and detoxifying enzymes, particularly glutathione-S-transferase and NAD(P)H dehydrogenase [quinone] 1 (NAD(P)H:quinone oxidoreductase; NQO1), resulting in the detoxification of highly reactive carcinogens. This accelerates the elimination of carcinogens, may protect against cellular damage, and prevents cancer formation. AREs are cis-acting regulatory enhancer elements found in the 5' flanking region of many phase II detoxification enzymes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0300F81F-2D6D-7EE7-E063-731AD00A408C","latestVersionIndicator":"Yes","beginDate":"2023-08-15","endDate":null,"createdBy":"LISU","dateCreated":"2023-08-15","modifiedBy":"LISU","dateModified":"2023-08-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0300F81F-2D6E-7EE7-E063-731AD00A408C","beginDate":"2023-08-15","endDate":null,"createdBy":"LISU","dateCreated":"2023-08-15","modifiedBy":"LISU","dateModified":"2023-08-15","deletedIndicator":"No"},{"value":"Binimetinib","valueDescription":null,"ValueMeaning":{"publicId":"4828187","version":"1","preferredName":"Binimetinib","longName":"4828187","preferredDefinition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Binimetinib","conceptCode":"C84865","definition":"An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2. Inhibition of MEK1/2 prevents the activation of MEK1/2 dependent effector proteins and transcription factors, which may result in the inhibition of growth factor-mediated cell signaling. This may eventually lead to an inhibition of tumor cell proliferation and an inhibition in production of various inflammatory cytokines including interleukin-1, -6 and tumor necrosis factor. MEK1/2 are dual-specificity threonine/tyrosine kinases that play key roles in the activation of the RAS/RAF/MEK/ERK pathway and are often upregulated in a variety of tumor cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"16717093-49B7-6644-E050-BB89AD434C5B","latestVersionIndicator":"Yes","beginDate":"2015-05-19","endDate":null,"createdBy":"REEVESD","dateCreated":"2015-05-19","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A6A18E-2799-63F7-E063-731AD00ADADA","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Dabrafenib","valueDescription":null,"ValueMeaning":{"publicId":"4539014","version":"1","preferredName":"Dabrafenib","longName":"4539014","preferredDefinition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dabrafenib","conceptCode":"C82386","definition":"An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"059E8F71-D4FF-7062-E050-BB89AD435032","latestVersionIndicator":"Yes","beginDate":"2014-10-17","endDate":null,"createdBy":"REEVESD","dateCreated":"2014-10-17","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A6A18E-279A-63F7-E063-731AD00ADADA","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Ivosidenib","valueDescription":null,"ValueMeaning":{"publicId":"6429532","version":"1","preferredName":"Ivosidenib","longName":"6429532","preferredDefinition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ivosidenib","conceptCode":"C114383","definition":"An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1), with potential antineoplastic activity. Upon administration, AG-120 specifically inhibits a mutated form of IDH1 in the cytoplasm, which inhibits the formation of the oncometabolite, 2-hydroxyglutarate (2HG). This may lead to both an induction of cellular differentiation and an inhibition of cellular proliferation in IDH1-expressing tumor cells. IDH1, an enzyme in the citric acid cycle, is mutated in a variety of cancers; it initiates and drives cancer growth by both blocking cell differentiation and catalyzing the formation of 2HG.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"75AC7369-E7A7-1EBD-E053-F662850A1EEE","latestVersionIndicator":"Yes","beginDate":"2018-09-12","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2018-09-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A6A18E-279D-63F7-E063-731AD00ADADA","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Larotrectinib","valueDescription":null,"ValueMeaning":{"publicId":"13673412","version":"1","preferredName":"Larotrectinib","longName":"13673412v1.00","preferredDefinition":"An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Larotrectinib","conceptCode":"C115977","definition":"An orally available, tropomyosin receptor kinase (Trk) inhibitor, with potential antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FC87891E-944E-016B-E053-731AD00A49C3","latestVersionIndicator":"Yes","beginDate":"2023-05-25","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-25","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A6A18E-279E-63F7-E063-731AD00ADADA","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Lorlatini","valueDescription":null,"ValueMeaning":{"publicId":"6117830","version":"1","preferredName":"Lorlatinib","longName":"6117830","preferredDefinition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lorlatinib","conceptCode":"C113655","definition":"An orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity. Upon administration, lorlatinib binds to and inhibits both ALK and ROS1 kinases. The kinase inhibition leads to disruption of ALK- and ROS1-mediated signaling and eventually inhibits tumor cell growth in ALK- and ROS1-overexpressing tumor cells. In addition, PF-06463922 is able to cross the blood brain barrier. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. ROS1, overexpressed in certain cancer cells, plays a key role in cell growth and survival of cancer cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"66EA6EE2-D4CE-1BC0-E053-F662850AA277","latestVersionIndicator":"Yes","beginDate":"2018-03-08","endDate":null,"createdBy":"PATELV","dateCreated":"2018-03-08","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A6A18E-279F-63F7-E063-731AD00ADADA","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Mirdametinib","valueDescription":null,"ValueMeaning":{"publicId":"7348903","version":"1","preferredName":"MEK Inhibitor PD0325901","longName":"7348903","preferredDefinition":"An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mirdametinib","conceptCode":"C52195","definition":"An orally bioavailable, synthetic organic molecule targeting mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. Upon administration, mirdametinib selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A9C6C6E1-3734-5FD0-E053-4EBD850AF325","latestVersionIndicator":"Yes","beginDate":"2020-07-06","endDate":null,"createdBy":"SPRINGERL","dateCreated":"2020-07-06","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A6A18E-27A0-63F7-E063-731AD00ADADA","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"ONC201","valueDescription":null,"ValueMeaning":{"publicId":"13956290","version":"1","preferredName":"Dordaviprone","longName":"13956290v1.00","preferredDefinition":"A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon administration, dordaviprone binds to and inhibits the activity of Akt and ERK, which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL death receptor type 5 (DR5) signaling in AKT/ERK-overexpressing tumor cells. The PI3K/Akt signaling pathway and MAPK/ERK pathway are upregulated in a variety of tumor cell types and play a key role in tumor cell proliferation, differentiation and survival by inhibiting apoptosis. In addition, ONC201 is able to cross the blood-brain barrier.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dordaviprone","conceptCode":"C113792","definition":"A water soluble, orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon administration, dordaviprone binds to and inhibits the activity of Akt and ERK, which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/TRAIL death receptor type 5 (DR5) signaling in AKT/ERK-overexpressing tumor cells. The PI3K/Akt signaling pathway and MAPK/ERK pathway are upregulated in a variety of tumor cell types and play a key role in tumor cell proliferation, differentiation and survival by inhibiting apoptosis. In addition, ONC201 is able to cross the blood-brain barrier.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FE3EC016-9A39-578C-E053-731AD00ADAE3","latestVersionIndicator":"Yes","beginDate":"2023-06-16","endDate":null,"createdBy":"SOKKERL","dateCreated":"2023-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7110A-2CB5-7810-E063-731AD00A2582","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"MMADDINENI","dateModified":"2023-09-18","deletedIndicator":"No"},{"value":"Palbociclib","valueDescription":null,"ValueMeaning":{"publicId":"3564160","version":"1","preferredName":"PD-0332991","longName":"3564160","preferredDefinition":"An orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. PD-0332991 selectively inhibits cyclin-dependent kinases (particularly Cdk4/cyclin D1 kinase), which may inhibit retinoblastoma (Rb) protein phosphorylation; inhibition of Rb phosphorylation prevents Rb-positive tumor cells from entering the S phase of the cell cycle (arrest in the G1 phase), resulting in suppression of DNA replication and decreased tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Palbociclib","conceptCode":"C49176","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. CDK4 and 6 are serine/threonine kinases that are upregulated in many tumor cell types and play a key role in the regulation of cell cycle progression.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C7DBA78C-8B81-5111-E040-BB89AD4317C1","latestVersionIndicator":"Yes","beginDate":"2012-08-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-08-22","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7110A-2CB6-7810-E063-731AD00A2582","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Pemetrexed","valueDescription":null,"ValueMeaning":{"publicId":"3237462","version":"1","preferredName":"Pemetrexed","longName":"3237462","preferredDefinition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pemetrexed","conceptCode":"C61614","definition":"A synthetic pyrimidine-based antifolate. Pemetrexed binds to and inhibits the enzyme thymidylate synthase (TS), which catalyses the methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) to 2'-deoxythymidine-5'-monophosphate (dTMP), an essential precursor in DNA synthesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A3F78E39-6570-13D6-E040-BB89AD432B2B","latestVersionIndicator":"Yes","beginDate":"2011-05-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-05-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7110A-2CB8-7810-E063-731AD00A2582","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Ribociclib","valueDescription":null,"ValueMeaning":{"publicId":"6072178","version":"1","preferredName":"Ribociclib","longName":"6072178","preferredDefinition":"An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ribociclib","conceptCode":"C95701","definition":"An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4 and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer, causes cell cycle deregulation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"65344B1A-4E61-24A6-E053-F662850A121F","latestVersionIndicator":"Yes","beginDate":"2018-02-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-02-14","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7110A-2CB9-7810-E063-731AD00A2582","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Selumetinib","valueDescription":null,"ValueMeaning":{"publicId":"3238481","version":"1","preferredName":"Selumetinib","longName":"3238481","preferredDefinition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selumetinib","conceptCode":"C66939","definition":"An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. MEK 1 and 2 are dual specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A41DC8A8-EBA5-0F50-E040-BB89AD436610","latestVersionIndicator":"Yes","beginDate":"2011-05-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-05-25","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7110A-2CBA-7810-E063-731AD00A2582","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Tazemetostat","valueDescription":null,"ValueMeaning":{"publicId":"13744020","version":"1","preferredName":"Tazemetostat","longName":"13744020v1.00","preferredDefinition":"An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tazemetostat","conceptCode":"C107506","definition":"An orally available, small molecule selective and S-adenosyl methionine (SAM) competitive inhibitor of histone methyl transferase EZH2, with potential antineoplastic activity. Upon oral administration, tazemetostat selectively inhibits the activity of both wild-type and mutated forms of EZH2. Inhibition of EZH2 specifically prevents the methylation of histone H3 lysine 27 (H3K27). This decrease in histone methylation alters gene expression patterns associated with cancer pathways and results in decreased tumor cell proliferation in EZH2 mutated cancer cells. EZH2, which belongs to the class of histone methyltransferases (HMTs), is overexpressed or mutated in a variety of cancer cells and plays a key role in tumor cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCA3B0EA-9F9A-6FCE-E053-731AD00A8D9F","latestVersionIndicator":"Yes","beginDate":"2023-05-26","endDate":null,"createdBy":"DWARZEL","dateCreated":"2023-05-26","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7110A-2CBB-7810-E063-731AD00A2582","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Tovorafenib","valueDescription":null,"ValueMeaning":{"publicId":"14478166","version":"1","preferredName":"Tovorafenib","longName":"14478166v1.00","preferredDefinition":"An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tovorafenib","conceptCode":"C106254","definition":"An orally available inhibitor of wild-type and certain mutant forms of A-Raf, B-Raf and C-Raf protein kinases, with potential antineoplastic activity. Upon administration, tovorafenib inhibits Raf-mediated signal transduction pathways, which may lead to an inhibition of tumor cell growth. Raf protein kinases play a key role in the RAF/MEK/ERK signaling pathway, which is often deregulated in human cancers and plays a key role in tumor cell proliferation and survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05A7110A-2CB4-7810-E063-731AD00A2582","latestVersionIndicator":"Yes","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7110A-2CBC-7810-E063-731AD00A2582","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Trametinib","valueDescription":null,"ValueMeaning":{"publicId":"3523220","version":"1","preferredName":"Trametinib","longName":"3523220","preferredDefinition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MEK MAPK/ERK kinase) with potential antineoplastic activity. Trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity threonine/tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Trametinib","conceptCode":"C77908","definition":"An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C4A309D0-4590-6212-E040-BB89AD4364ED","latestVersionIndicator":"Yes","beginDate":"2012-07-12","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-07-12","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7110A-2CBD-7810-E063-731AD00A2582","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Vemurafenib","valueDescription":null,"ValueMeaning":{"publicId":"3422122","version":"1","preferredName":"Vemurafenib","longName":"3422122","preferredDefinition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Vemurafenib","conceptCode":"C64768","definition":"An orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation. Approximately 90% of BRAF gene mutations involve a valine-to-glutamic acid mutation at residue 600 (V600E); the oncogene protein product, BRAF(V600E) kinase, exhibits a markedly elevated activity that over-activates the MAPK signaling pathway. The BRAF(V600E) gene mutation has been found to occur in approximately 60% of melanomas, and in about 8% of all solid tumors, including melanoma, colorectal, thyroid and other cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BC3ACCEE-3440-DAF6-E040-BB89AD433B37","latestVersionIndicator":"Yes","beginDate":"2012-03-27","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-03-27","modifiedBy":"KUMMEROA","dateModified":"2023-09-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05A7110A-2CBE-7810-E063-731AD00A2582","beginDate":"2023-09-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-09-18","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"ONC206","valueDescription":null,"ValueMeaning":{"publicId":"14483679","version":"1","preferredName":"DRD2 Antagonist/ClpP Agonist ONC206","longName":"14483679v1.00","preferredDefinition":"An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, with potential antineoplastic activity. Upon administration, DRD2 antagonist/ClpP agonist ONC206 targets, binds to and inhibits the activity of DRD2. This may inactivate Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/death receptor type 5 (DR5; TRAIL receptor 2) signaling in tumor cells. In addition, ONC206 targets and binds to ClpP and induces proteolysis. This may disrupt mitochondrial structure and function in tumor cells and lead to tumor cell death. DRD2, a G protein-coupled receptor (GPCR), is overexpressed in various malignancies. It is activated by dopamine produced by the tumor cells or present in the tumor microenvironment (TME) and plays an important role in the pro-survival and stress signaling pathways. ONC206 is able to cross the blood-brain barrier (BBB).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DRD2 Antagonist/ClpP Agonist ONC206","conceptCode":"C176975","definition":"An orally bioavailable, selective bitopic dopamine receptor D2 (DRD2) antagonist and mitochondrial caseinolytic protease P (ClpP) agonist, with potential antineoplastic activity. Upon administration, DRD2 antagonist/ClpP agonist ONC206 targets, binds to and inhibits the activity of DRD2. This may inactivate Akt (protein kinase B) and extracellular signal-regulated kinase (ERK), which may result in inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway as well as the mitogen-activated protein kinase (MAPK)/ERK-mediated pathway. This may lead to the induction of tumor cell apoptosis mediated by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)/death receptor type 5 (DR5; TRAIL receptor 2) signaling in tumor cells. In addition, ONC206 targets and binds to ClpP and induces proteolysis. This may disrupt mitochondrial structure and function in tumor cells and lead to tumor cell death. DRD2, a G protein-coupled receptor (GPCR), is overexpressed in various malignancies. It is activated by dopamine produced by the tumor cells or present in the tumor microenvironment (TME) and plays an important role in the pro-survival and stress signaling pathways. ONC206 is able to cross the blood-brain barrier (BBB).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"05BC7C2E-28A5-5471-E063-731AD00AEA2B","latestVersionIndicator":"Yes","beginDate":"2023-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-19","modifiedBy":"GDEEN","dateModified":"2024-01-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05BC7C2E-28A6-5471-E063-731AD00AEA2B","beginDate":"2023-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-19","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Selinexor","valueDescription":null,"ValueMeaning":{"publicId":"6618084","version":"1","preferredName":"Selinexor","longName":"6618084","preferredDefinition":"An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Selinexor","conceptCode":"C102546","definition":"An orally available, small molecule inhibitor of CRM1 (chromosome region maintenance 1 protein, exportin 1 or XPO1), with potential antineoplastic activity. Selinexor modifies the essential CRM1-cargo binding residue cysteine-528, thereby irreversibly inactivates CRM1-mediated nuclear export of cargo proteins such as tumor suppressor proteins (TSPs), including p53, p21, BRCA1/2, pRB, FOXO, and other growth regulatory proteins. As a result, this agent, via the approach of selective inhibition of nuclear export (SINE), restores endogenous tumor suppressing processes to selectively eliminate tumor cells while sparing normal cells. CRM1, the major export factor for proteins from the nucleus to the cytoplasm, is overexpressed in a variety of cancer cell types.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"801EA03E-93C2-7862-E053-F662850A4F83","latestVersionIndicator":"Yes","beginDate":"2019-01-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-01-23","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"05BC7C2E-28A7-5471-E063-731AD00AEA2B","beginDate":"2023-09-19","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2023-09-19","modifiedBy":"KUMMEROA","dateModified":"2023-09-19","deletedIndicator":"No"},{"value":"Apalutamide/Placebo","valueDescription":null,"ValueMeaning":{"publicId":"14665313","version":"1","preferredName":"Apalutamide Or Placebo","longName":"14665313v1.00","preferredDefinition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Apalutamide","conceptCode":"C92574","definition":"A small molecule and androgen receptor (AR) antagonist with potential antineoplastic activity. Apalutamide binds to AR in target tissues thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes. This ultimately inhibits the expression of genes that regulate prostate cancer cell proliferation and may lead to an inhibition of cell growth in AR-expressing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0CCDA454-AD6F-329B-E063-731AD00A5E8A","latestVersionIndicator":"Yes","beginDate":"2023-12-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-12-18","modifiedBy":"MMADDINENI","dateModified":"2023-12-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0CCDA454-AD70-329B-E063-731AD00A5E8A","beginDate":"2023-12-18","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2023-12-18","modifiedBy":"MMADDINENI","dateModified":"2023-12-18","deletedIndicator":"No"},{"value":"Urolithin A/Placebo","valueDescription":null,"ValueMeaning":{"publicId":"14673133","version":"1","preferredName":"Urolithin A Supplement Or Placebo","longName":"14673133v1.00","preferredDefinition":"A dietary supplement composed of urolithin A (Uro-A) that may be used to modulate mitochondrial activity, and with potential antioxidant and anti-inflammatory activities. Upon oral administration, urolithin A supplement activates mitophagy, which may improve mitochondrial and cellular health. Urolithin A, one of the natural polyphenolic metabolites of ellagic acid and ellagitannins produced by the gut microbiota, also acts as a direct free radical scavenger, which may protect against inflammation- and reactive oxygen species (ROS)-induced cellular damage._An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise._An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Urolithin A Supplement","conceptCode":"C199310","definition":"A dietary supplement composed of urolithin A (Uro-A) that may be used to modulate mitochondrial activity, and with potential antioxidant and anti-inflammatory activities. Upon oral administration, urolithin A supplement activates mitophagy, which may improve mitochondrial and cellular health. Urolithin A, one of the natural polyphenolic metabolites of ellagic acid and ellagitannins produced by the gut microbiota, also acts as a direct free radical scavenger, which may protect against inflammation- and reactive oxygen species (ROS)-induced cellular damage.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Or","conceptCode":"C37998","definition":"An article used to connect words, phrases, or clauses representing alternatives; used to connect alternative terms for the same thing; used in correlation; used to correct or rephrase what was previously said; otherwise.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Placebo","conceptCode":"C753","definition":"An inactive substance, treatment or procedure that is intended to provide baseline measurements for the experimental protocol of a clinical trial.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0E77D8F8-802A-1A22-E063-731AD00ADB72","latestVersionIndicator":"Yes","beginDate":"2024-01-08","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-08","modifiedBy":"MMADDINENI","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"0E77D8F8-802B-1A22-E063-731AD00ADB72","beginDate":"2024-01-08","endDate":null,"createdBy":"MMADDINENI","dateCreated":"2024-01-08","modifiedBy":"MMADDINENI","dateModified":"2024-01-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4F5148FD-83A6-3F65-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"MMADDINENI","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":"2023.4.12 Added missing PVs defs where 'No value exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811831","version":"1","longName":"Breast","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"3896529","version":"1","longName":"Consortia 2012 Studies","context":"DCP","ClassificationSchemeItems":[{"publicId":"5280818","version":"1","longName":"UWI2014-03-01","context":"DCP"},{"publicId":"5441476","version":"1","longName":"MDA2014-04-02","context":"DCP"},{"publicId":"5889176","version":"1","longName":"MDA2016-07-02","context":"DCP"},{"publicId":"5889177","version":"1","longName":"MDA2016-08-02","context":"DCP"}]}],"AlternateNames":[{"name":"ECOG-ACRIN","type":"USED_BY","context":"ECOG-ACRIN"},{"name":"DCP","type":"USED_BY","context":"DCP"},{"name":"Alliance","type":"USED_BY","context":"Alliance"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"NRG","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Agent","type":"Preferred Question Text","description":"Agent","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Agent name","url":null,"context":"CTEP"},{"name":"CRF Text 2","type":"Alternate Question Text","description":"Treatment name","url":null,"context":"CTEP"},{"name":"ECOG CRF Text 1","type":"Alternate Question Text","description":"Agent administered","url":null,"context":"ECOG-ACRIN"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Agent name:","url":null,"context":"CTEP"},{"name":"CRF_Text_3","type":"Alternate Question Text","description":"Treatment name","url":null,"context":"CTEP"},{"name":"DCP Question Text","type":"Alternate Question Text","description":"Patient Randomized to Receive","url":null,"context":"DCP"},{"name":"DCP Question Text - 2","type":"Alternate Question Text","description":"Inoculation","url":null,"context":"DCP"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Cytoreduction drug administered:","url":null,"context":"COG"},{"name":"CRF Text4","type":"Alternate Question Text","description":"Regimen name","url":null,"context":"Alliance"},{"name":"CRF Text5","type":"Alternate Question Text","description":"Drug Name","url":null,"context":"Alliance"},{"name":"CRF Text6","type":"Alternate Question Text","description":"Therapy name","url":null,"context":"Alliance"},{"name":"COG CRF Text 7","type":"Alternate Question Text","description":"Agents administered:","url":null,"context":"COG"},{"name":"DCP-Text-3","type":"Alternate Question Text","description":"Agent Name","url":null,"context":"DCP"},{"name":"DCP-Text-4","type":"Alternate Question Text","description":"Prior Cytotoxic Chemotherapy","url":null,"context":"DCP"},{"name":"DCP-Text-5","type":"Alternate Question Text","description":"Agent/Placebo","url":null,"context":"DCP"},{"name":"DCP-Text-6","type":"Alternate Question Text","description":"Treatment","url":null,"context":"DCP"},{"name":"NRG CRF Text","type":"Alternate Question Text","description":"Which immunotherapy regimen is selected for the patient?","url":null,"context":"NRG"},{"name":"COG CRF Text 3","type":"Alternate Question Text","description":"Protocol therapy agent:","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Which agents","url":null,"context":"COG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Agent administered:","url":null,"context":"COG"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"Type of Methotrexate administered during this reporting period","url":null,"context":"COG"}],"origin":"ACOSOG CRF:American College of Surgeons Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"4F51590F-BF16-4421-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2008-06-10","modifiedBy":"KUMMEROA","dateModified":"2023-11-17","changeDescription":null,"administrativeNotes":"2023.11.17 AQT added per ticket request CADSR0003092. ak 2023.10.19 AQT added per ticket request CADSR0002984. ak 09/18/2023-Added PVs (CADSR0002859)-MM 2022.9.16 AQT added per email. ak","unresolvedIssues":null,"deletedIndicator":"No"}}